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ABSTRACT
BURDEN AND RISK OF NON-AIDS DEFNING CANCERS IN HIV-INFECTED
PERSONS RECEIVING ANTIRETROVIRAL THERAPY
Brittney L. Dickey, Ph.D.
University of Nebraska, 2019
Supervisor: Christine M. Arcari, Ph.D.
The burden of cancers not previously associated with an HIV infection, called non-AIDS
defining cancers (NADCs), have increased in the years since highly active anti-retroviral therapy
has been introduced. The studies in this dissertation attempted to quantify this burden via
incidence and mortality compared to the general population. Further, an assessment of risk
factors and creation of a predictive risk model, a nomogram, were utilized to better understand
how factors associated with demographics, lifestyle, and immune response affected risk for an
NADC diagnosis once therapy was initiated and HIV better controlled. Standardized incidence
and mortality ratios showed that burden of NADC is much higher among HIV-infected persons,
and especially among those cancers with a viral etiology such as anal cancer (SIR: 312.2; SMR:
347.2), Hodgkin’s lymphoma (SIR: 97.5; SMR: 140.8), and liver cancer (SIR: 30.9; SMR: 35.5).
NADCs not associated with a viral etiology were also increased including lung cancer (SIR: 14.3;
SMR: 17.0) and melanoma (SIR: 6.2; SMR: 11.0). Multivariate cox regression for viral associated
NADCs found that age (HR: 2.71; 95% CI: 1.84-3.98), prior AIDS-defining infection (HR: 1.42; 95%
CI: 1.04-1.93), and Hepatitis B (HR: 2.44; 95% CI: 1.68-3.55) increased risk. Risk for non-viral
associated NADCs increased with older age (HR: 12.8; 95% CI: 8.57-19.1) and tobacco use (HR:
1.3; 95% CI: 1.07-1.60). The nomogram had average ability to predict a person’s chance of
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developing a viral- or non-viral associated NADCs (c-index of 0.466 and 0.497, respectively). It
did, however, identify factors related to immune status (nadir CD4 and CD4 change) as the most
important factors for viral-associated NADC risk; and older age as the most important factor for
non-viral associated NADC risk. Future studies should investigate individual NADC sites’ risk
factors and utilize genetic epidemiology to understand the interplay of post-ART immune
response factors with lifestyle risk factors for cancer.
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INTRODUCTION
HIV/AIDS in the United States
The latest HIV surveillance reports estimate that there are currently over 1.1 million people
living with an HIV infection in the U.S. and 38,739 new cases of HIV diagnosed in 2017 (Centers for
Disease Control and Prevention, 2018). However, the current incidence of an HIV diagnosis has
remained stable since 2012 and most recent data shows an incidence rate of 11.8 per 100,000 in 2017
and a prevalence of 306.6 per 100,000. Mortality among persons diagnosed with HIV decreased and
was most recently shown to be 4.8 per 100,000 in 2016.
Sex. Males account for 81% of all new cases of HIV and had an incidence rate of 23.1 per
100,000 compared to women at a rate of 5.2 per 100,000. Male prevalence rate was 570.1 per 100,000
and 169.9 per 100,000 for females. Mortality among males was 8.8 per 100,000 and 2.7 per 100,000
among females (Centers for Disease Control and Prevention, 2018).
Race/Ethnicity. African Americans experience the highest burden of HIV infection compared to
other races and ethnicities with an incidence of 43.6 per 100,000, a prevalence of 1,026.6 per 100,000
and account for 45% of the HIV population, but only 12% of the U.S. population. They are followed by
Hispanics/Latinos with an incidence of 17.0 per 100,000, a prevalence of 372.1 per 100,000, and
constitute 24% of HIV diagnoses, but only 18% of the general population. The highest rate of mortality
was among African Americans (16.9 per 100,000) (Centers for Disease Control and Prevention, 2018).
Transmission Category. The percentage of HIV cases attributed to male-to-male (MSM) sexual
contact is 70%, heterosexual contact was 24%, injection drug use (IDU) was 6%, and 3% were attributed
to MSM and IDU. Black, male-to-male sexual contact represented the majority of new diagnoses in
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2017, followed by Hispanic male-to-male sexual contact and white male-to-male contact (Figure 1)
(Centers for Disease Control and Prevention, 2018).

Figure 1. New HIV Diagnoses in the US for the Most-Affected Subpopulations, 2017.

Age. Among all HIV infected individuals diagnosed in 2015, those aged 25-29 account for the
highest burden of HIV-infected in the U.S. with an incidence of 32.9 per 100,000. The next most
affected age range is 20-24, with a rate of 28.7 per 100,000. However, prevalence is currently highest
among 50-54 year-olds (777.6 per 100,000) and 45-49 year-olds (661.6 per 100,000). Mortality has
increased among 60-64 year-olds and those 65 and older, but has decreased or remained stable in all
other age groups (Centers for Disease Control and Prevention, 2018).
Region. Disparities also exist geographically, with the South seeing the highest rates of new HIV
diagnoses (16.8 per 100,00), followed by the Northeast (11.6), the West (9.8), and the Midwest (7.6).
Prevalence and mortality, though, was highest in the Northeast (418.8 per 100,000 and 6.4 per 100,000),
followed by the South (361.3 and 6.1), the West (253.7 and 3.4) and the Midwest (174.5 and 2.5)
(Centers for Disease Control and Prevention, 2018).
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The rates of new HIV cases diagnosed each year has continued to decrease since 2010. In the
overall population, there have been 9% fewer new cases diagnosed since 2010. Specifically, rates
among white gay and bisexual men have decreased by 9%, rates among black gay and bisexual men
have increased 2%; they have increased 13% among Hispanic/Latino gay and bisexual men. Among all
heterosexuals, there has been a decline of 19%; among all women a decline of 20%; and among
injection drug users (IDUs), a decline of 32% (Centers for Disease Control and Prevention, 2018).

Progression to AIDS after HIV Infection
Untreated HIV infection leads to AIDS. As HIV replicates in the body, immune function weakens
leading to immunodeficiency, opportunistic infections, and, potentially, death. Immune function is
measured by CD4 counts, and an HIV infected person with CD4 counts below 200 cells/mm3 is
diagnosed with stage III HIV infection and called Acquired Immunodeficiency Syndrome (AIDS). In 2017,
the rate of new AIDS diagnoses was 5.4 per 100,000. The highest incidence of AIDS was among 30-34
years old (11.1 per 100,000); African Americans (20.5 per 100,000); and males (10.0 per 100,000).
Mortality in 2016 among those diagnosed with AIDS was 3.8 per 100,000 (Centers for Disease Control
and Prevention, 2018) (AVERT, 2016).
The onset of AIDS can be marked by the diagnoses of several diseases or conditions called AIDSdefining conditions. They include cryptococcal meningitis, toxoplasmosis, certain types of pneumonia,
esophageal candidiasis, and certain cancers including Kaposi’s sarcoma (KS) and non-Hodgkin’s
lymphoma (NHL) (AVERT, 2016). The extensive list as defined by the CDC can be seen in Figure 2 (Hirsch,
Kaufmann, Sendi, & Battegay, 2004).
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Figure 2. AIDS-defining conditions

The progression to AIDS can be prevented with immediate and adherent treatment using one or
more forms of anti-retroviral therapy (ART). Early initiation of ART and adherence to a successful
treatment regimen reduces virus circulating in the body, often to undetectable levels, and immune
function can be restored (Hirsch, Kaufmann, Sendi, & Battegay, 2004) (Bartlett, 2016). A small
percentage of HIV-infected patients never progress to AIDS and are able to maintain proper immune
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function without ART (Bartlett, 2016). However, in most cases, ART of some kind is required to keep the
infection at undetectable levels.

Treatment of HIV and associated clinical measures
The first treatment for HIV, Zidovudine (AZT), was first introduced in 1990. AZT was a single drug
treatment regimen and it was quickly realized that a single drug could not combat an HIV infection for
long and often led to the rapid development of drug resistance in most patients (HIV.gov, 2019). Multidrug HIV treatment regimens were started in the early 1990s to better control the complex attack
mechanisms of the HIV virus. In the 1990s studies that combined AZT with a new drug, a nucleoside
reverse transcriptase inhibitor (NRTI), using a two-drug therapy found higher efficacy in management of
HIV compared to using AZT alone. In 1995, the first protease inhibitor (PI) was approved for use in HIV
care and thus began an era of “highly active antiretroviral therapy” (HAART) which would become the
HIV standard of care still used today. HAART is a combination of three or more antiretroviral drugs,
selected for each individual patient’s case (AIDS.gov, 2019) (Centers for Disease Control and Prevention,
2019). Researchers eventually found that triple-drug therapy could effectively suppress HIV replication
to minimal levels and inhibit drug resistance. It was discovered that the combination of using a PI plus
two NRTIs was the most effective combination and is still considered as such to date (NIAIDS, 2019).
Since then, HAART has progressed to now include 5 classes of drugs that target the virus in different
ways. A sixth type is a multi-class combination that includes two or more of classes in a single tablet.
The 6 classes of HIV treatment medications are (NIAIDS, 2019):
Entry Inhibitors interfere with the ability of the virus to bind to cells, thus HIV cannot infect the cell.
Fusion Inhibitors interfere with the virus’s ability to fuse to the cellular membrane and thus the
virus cannot enter the cell.
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Reverse Transcriptase Inhibitors Prevents HIV single stranded RNA (ssRNA) from converting to
double stranded DNA (dsDNA) by blocking the reverse transcriptase (RT) and includes 2 types:
Nucleoside/nucleotide RT inhibitors (NRTIs) are faulty DNA building blocks; when they are
added to the growing dsDNA chain no further blocks can be added, stopping DNA synthesis
Non-nucleoside RT inhibitors (NNRTIs) bind to the RT, halting its ability to convert ssRNA to
dsDNA
Integrase Inhibitors: block HIV enzyme integrase. Thus, the HIV cannot integrate its DNA into the
host cells.
Protease Inhibitors interfere with HIV enzyme protease, meaning long chains of HIV proteins cannot
be cut into smaller proteins, thus no new virus particles are assembled.
Multi-class combination products combine at least 2 drugs types into a single product.
HIV treatment is essential to keep the HIV virus at the lowest possible level and maintain immune
function to prevent AIDS-related conditions. Routine care for a newly HIV infected patient involves
frequent visits to a specialized physician and include measures of HIV and immune function at each visit
to determine if the current line of care is working for the patient. A measure of the extent of HIV
infection is assessed by a count of CD4 T cells, to assess immune function, and viral load, to detect the
amount of virus in the body. CD4 count is often the most reliable measure as viral load can fluctuate
daily (Bartlett, 2016).
Initiation of ART and adherence to a successful regimen will increase the CD4 counts and suppress
the viral load as the treatment inhibits HIV replication. After initiating HAART, there is an initial rapid
increase in CD4 counts observed within the first 3-6 months followed by a slower increase (Hirsch,
Kaufmann, Sendi, & Battegay, 2004). A CD4 count greater than 500 cells/mm3 is usually a marker for
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restored immune function, while a count of less than 200 cells/mm3 is a marker for depleted immune
function, and less than 50 cells/mm3 is a severely depressed immune function. An AIDS defining illness
can develop 12-18 months from the time the CD4 count falls below 200 cells/mm3. Those that die of an
AIDS associated complication typically have a CD4 count <50 cells/mm3 (Bartlett, 2016). Viral load
should begin to fall with the right HAART. With strict adherence to the right formulation, a patient’s
viral load should fall to undetectable levels, which is usually below 50 copies/ml. An undetectable viral
load is beneficial, because it means a patient is at reduced risk to develop other conditions, and it means
they are less likely to become resistant to the current line of treatment. Viral load can fluctuate and
thus an individual measurement should be interpreted with the CD4 count and often in relation to a
patient’s viral load trend since HAART initiation (Pebody, 2017).
While ART is a crucial step in the treatment of HIV and prevention of AIDS, there are potential
complications. First, immune reconstitution syndrome (IRS) is estimated to occur in 10-25% of patients
who are receiving ART. IRS is defined as “paradoxical worsening of clinical or laboratory parameters
despite favorable development of the HIV surrogate markers”. It typically occurs in patients with a CD4
count <50 cells/mm3 and occurs within the first 8 weeks of treatment, but can occur as late as several
months after initiation of treatment (Hirsch et al., 2004). In short, while a patient responds positively to
HAART and immune function is improving, a pre-existing infection, whether recognized or not, emerges
(Sexton & Pien, 2019).
Since HAART’s widespread adoption in the U.S. in 1996 dramatic decreases in AIDS-related mortality
and morbidity have been observed. In addition, use of HAART effectively increases the lifespan of
someone living with HIV. Life expectancy for a 20-year old living with HIV and on HAART increased from
36.1 years to 51.4 years during the years 2000-2007 (Samji, et al., 2013). While having an HIV infection
that is well treated increases survival and decreases risk of developing AIDS, new challenges in disease
management present due to people living longer and remaining on HAART longer than ever before.
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HIV is a lifelong condition, that requires strict adherence and care management. At this time, a
patient may never expect to rid themselves of the infection and so proper treatment to live a long life is
essential (Deeks, Lewin, & Havlir, 2013). With advances in HIV treatment that have led to prolonged
survival, HIV infection has become a chronic disease, and while AIDS may be prevented, a new host of
problems referred to as “non-AIDS morbidity” is now a concern. Now, patients adhering to treatment
and who have experienced suppressed HIV are at risk of several non-AIDS conditions such as
cardiovascular disease, cancer, kidney disease, liver disease, and neurocognitive disease (Deeks, Lewin,
& Havlir, 2013).

Cancer Risk in HIV-infected Persons
A consequence of improved and successful treatment for HIV infection with HAART is a life
expectancy now approaching that of the general population, and the development of chronic diseases
such as cancer are more common now in the HIV-infected population. Three cancers, Kaposi’s Sarcoma
(KS), invasive cervical cancer and non-Hodgkin’s Lymphoma (NHL) define the onset of AIDS. These
cancers are associated with the lack of HAART and declining immune function and are referred to as
AIDS-defining cancers (ADCs). Changes in treatment have led to decreases in co-morbidities associated
with HIV and the development of AIDS-related conditions, specifically ADCs. However, improved
treatments that led to more years of life lived, also led to an aging HIV-infected population. All other
cancers, called non-AIDS defining cancers (NADCs), are also now affecting the HIV-infected population.
Cancer risk in the HIV-infected population can be assessed as pre-HAART risk (approximately
1991-1995) and post-HAART risk (approximately 2001-2005). When comparing the two eras, ADCs
decreased greater than threefold from pre to post-HAART eras, while NADCs increased threefold (Shiels,
et al., 2011). The largest absolute increases for specific types of NADCs included anal cancer, lung
cancer, prostate cancer, Hodgkin lymphoma, and liver cancer and about 50% of the NADCs in the study
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population were from cancers of the lung, anus, liver and Hodgkin lymphoma. The decreased rates of
the ADCs are not surprising due to the prevention of AIDS and its associated illnesses related to
introduction of HAART. However, it is less clear why they NADCs increased this much. Several factors
have been associated with this increase. First, the population living with HIV/AIDS increased fourfold
between the two eras, thus resulting in even more people at risk. Second, there is an increasing
proportion of HIV-infected people surviving over the age of 40 who now begin to reach ages associated
with most NADCs in the general population. Finally, there was a large observed incidence in some of the
NADCs that seem to be showing up more frequently in this population (Figure 3) (Shiels, et al., 2011).

Figure 3. Shiels et al., shows the increasing HIV population in the U.S., declining rates of ADCs, and increasing rates of NADCs.
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The cancers most likely to present in an HIV-infected patient are those related to an oncogenic
viruses such as HPV related to cervical and anal cancers or Hepatitis B and Hepatitis C infection related
to liver cancer; or those related to lifestyle factors that are prominent in the HIV-infected. These
oncogenic viruses have the same route of transmission as HIV (sexual transmission and injection drug
use) and thus it is not uncommon that an HIV-infected person may also be infected with HPV, Hepatitis
B, or Hepatitis C. The risk of cancers associated with infections is increased in the HIV-infected because
of greater prevalence of these infections in this population and their loss of ability to fend off the
infections due to their partially suppressed immune system (Silverberg, et al., 2009). There are also
lifestyle factors that occur more commonly in in the HIV-infected population, such as smoking and
alcohol use, that are linked to risk of lung or liver cancers (Engels, et al., 2008). Due to the variety of
factors that could be at play each needs to be considered in association with NADCs.

Factors associated with NADC Risk in the HIV-infected population
Many of the NADCs are highly associated with lifestyle factors or co-infections that exist at a
higher rate in the HIV-infected population compared to the general population, thus playing a greater
role in risk for cancers in the HIV-infected population. The most prominent lifestyle factors considered
are tobacco use, injection drug use, alcohol use, and risky sexual behaviors that can predispose a person
to STIs, especially HPV. Co-infections with HBV, HCV, HPV, and Epstein-Barr virus (EBV) are likewise
important risk factors for NADCs.

Oncogenic Viruses
In 2008, 16.1% of all new cancer cases were attributed to an infectious agent. Among those
cancers, 29.5% were attributed to HBV/HCV, 30.0% to HPV, and 5.4% to EBV. In North America,
specifically 4.0% of all cancers were attributable to an infectious agent (de Martel, et al., 2012). HIVinfected patients have an increased risk of cancer-causing viruses because of the similar exposure routes
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to HIV. Among HIV-positive persons, specifically, cancers associated with a virus are important to
consider. HIV-positive persons already have a compromised immune system due to HIV and HIV-related
treatments. The only line of defense against viruses is a person’s immune system, and with a
compromised immune system and a virus already present, the defense is limited. Therefore, when
considering cancer risk among the HIV-positive, viral etiology is an important consideration (Deeken, et
al., 2012).
Hepatitis B (HBV), like HIV, is a lifelong infection that must be properly managed with
antiretroviral treatment and in the U.S. approximately 6-10% of HIV-infected individuals are also
infected with HBV (Singh, Crane, Audsley, & Lewin, 2017). Hepatitis C is estimated to be present in 25%
of all HIV-infected persons in the U.S. (AIDSinfo, 2019). Among HIV-infected, HBV-related liver cancer
seems to be at increased risk in the presence of immunosuppression, specifically lower CD4 counts.
HCV-related liver cancer thus far does not seem to be related to immunosuppression (Shiels & Engels,
Evolving epidemiology of HIV-associated malignancies, 2017).
EBV, while present in 20-50% Hodgkin’s lymphoma in the general population, is much higher
among the HIV-infected. Current estimates have found that 75%-100% of Hodgkin’s lymphoma among
those with HIV are EBV associated. Further, the impairment of the EBV-specific CD4+ T-cell response
may further predispose one to Hodgkin’s lymphoma (Deeken, et al., 2012).
Finally, HPV is a common co-infection among HIV-infected persons. HIV-positive persons are
more likely to be HPV infected compared to HIV-negative persons. An exact proportion of HIV-positive
persons with an HPV co-infection is difficult, due to the virus existing in only the infected tissues such as
the anus, cervix, or pharynx. However, reports from small cohort studies have found proportions such
as: 88% of HIV-positive MSM had an anal HPV infection, 97% of HIV-positive women had cervical HPV
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infection and 20% had an oral HPV infection. HPV has also been associated with penile cancer, vulvar
cancer (Palefsky, 2009).

Smoking
About 19% of the general population are cigarette smokers while the HIV-infected population
has smoking rates closer to 40% (Kirk et al., 2007) and some estimates even cite smoking rates as high as
70% among HIV-infected (Petoumenos & Law, 2016). Not only does smoking increase a patient’s risk of
lung cancer, but in HIV-infected populations it is also related to bacterial pneumonia and pulmonary
disease (Petoumenos & Law, 2016). In addition to putting them at increased risk of comorbid disease,
HIV-positive smokers experienced 12.3 year reduced life expectancy compared to only 5.1 life-years lost
in HIV-uninfected population controls who smoked (Petoumenos & Law, 2016). HIV-infected persons are
also less likely to quit smoking (32.4%, 95% CI: 29.6%-35.3%) than HIV uninfected persons (51.7%, 95%
CI: 50.3%-53.0%) (Mdodo, et al., 2015).
When looking at smoking specifically related to lung cancer risk, current smoking in HIV-infected
patients was associated with an adjusted hazard ratio of 9.4 (95% CI: 1.1-76.3) for lung cancer compared
to HIV-infected non-smokers (Lifson, et al., 2010). Death after a lung cancer diagnosis also was different
with HIV-positive patients. Those diagnosed with lung cancer had a 50% chance of death within one
year of diagnosis, and 77% by 2.5 years since diagnosis (Petoumenos & Law, 2016).

Injection Drug Use
Injection drug use (IDU) continues to be a common mode of transmission of HIV in the U.S.
About 1 in 10 new cases of HIV will be the result of IDU or men who have sex with men and IDU (Centers
for Disease Control and Prevention, 2019). Further, transmission of HIV by IDU has been shown to
impact survival even after HAART. In the most recent era of HAART use, HIV-infected patients’ relative
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hazard (RH) of progression to an AIDS defining event or death was 16% for low CD4 counts and 34% for
high CD4 counts. Whereas, among HIV-infected IDUs the relative hazard was 65% (low CD4) and 135%
(high CD4) (Poundstone, Chaisson, & Moore, 2001). Not only does IDU affect survival, but it puts a
patient at risk of Hepatitis B and Hepatitis C—both related to liver cancer and both with similar means of
acquiring the infection (Shiels & Engels, Evolving epidemiology of HIV-associated malignancies, 2017).

Alcohol Use
Of the HIV-infected patients in current routine care, 53% reported drinking alcohol in the
preceding month and rates of hazardous drinking among the same group are more than twice the
estimated rates of the general population with reported rates of 8-54% (Hutton, et al., 2013). Increased
alcohol use, as well as other substance use, is associated with poorer adherence to a patient’s ART and
has even been associated with an increase in mortality by 25-35% (Petoumenos & Law, 2016). In
addition to poor ART adherence, excessive alcohol use has been related to increased risk of liver disease,
including liver cancer, and risky sexual behaviors including inconsistent use of condoms and multiple sex
partners while under the influence of alcohol (Hutton, et al., 2013).
Alcohol use does seem to vary across HIV-infected subpopulations. High rates of excessive
alcohol use have been mostly found among men who have sex with men (MSM) and lower socioeconomic classes. The use of alcohol is also related to use of other substances including marijuana, IDU,
or other non-injection drugs. HIV-positive smokers, for example, are also more likely to use alcohol in
excess (Petoumenos & Law, 2016).
One prominent concern of excess alcohol use in HIV-infected persons is how the side effects
inhibit the person’s ability to adhere to a highly ordered and time-sensitive ART regimen. In a study of
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183 HIV-positive patients, alcohol use was associated with reduced adherence to ART and was also
related to missing medications when drinking. These periods of non-adherence can be particularly
problematic because the virus can become resistant to treatment during periods of little or no ART use
(Kalichman S. C., et al., 2014). While accidental non-adherence is a concern with alcohol use, so, too, is
intentional non-adherence. Studies have found that non-adherence can be intentional due to a patient’s
perceived toxicity of taking ART while using recreational drugs (Kalichman, et al., 2015). Alcohol use was
less common among those who were adherent to their ART (Scott-Sheldon, et al., 2013).
Alcohol Use & Risk Sexual Behaviors. Finally, while increased alcohol use is known to be high
among HIV-infected persons and lead to some adverse outcomes, it is particularly problematic since it
also leads to an increase in risky sexual behaviors. One in three HIV-infected persons who drink alcohol
and are taking ART are more likely to engage in unprotected anal or vaginal intercourse with HIVuninfected partners (Kalichman S. , et al., 2013). Further, it is linked to increasing rates of HIV
transmission due to its association with the likelihood of unprotected sex. In 2010, MSM accounted for
63% of new HIV cases in the U.S, an increase from 53% in 2006. Transmission between MSM has been
linked to excess alcohol use especially in situations involving unprotected anal intercourse (UAI). In one
study of MSM, the risk of an HIV-positive man having UAI with another man with unknown or negative
HIV status occurred after 12 or more drinks. This risk was not present with 5-12 drinks and, in contrast,
increased odds of protected anal intercourse occurred at 5 or more drinks, suggesting that UAI only
occurs with excess levels of alcohol use (Kalichman, et al., 2015). Many patients living with HIV
reporting remaining sexually active, with many also reporting participation in unprotected sex. Among
HIV-positive MSM who had HIV for a median time of 70 months, 26% reported that they engaged in UAI
(Scott-Sheldon, et al., 2013).
While these risky sexual behaviors are problematic regarding HIV transmission, it also exposes
HIV-positive patients to other STI’s. Infection by other STIs have been shown to cause HIV viral shedding
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in the genital tract, thus increasing risk for transmission. Further, risky sexual behaviors put one at risk
for HPV and HBV, both highly associated to several NADCs (Kalichman S. , et al., 2013).
In summary, all the lifestyle factors discussed are associated with HIV and correlated to risk of
cancer in both the HIV and general population. Smoking is highly associated with lung cancer and has
been also linked to head and neck cancers. Injection drug use is associated with not only acquiring HIV,
but also Hepatitis B and Hepatitis C infections—both linked to liver cancer. Alcohol use, while complex
in its association can be linked to several cancers. Alcohol use is associated with cancer risk in general.
Specifically, it can lead to liver disease which predisposes one to liver cancer. Additionally, alcohol use is
strongly linked to risky sexual behaviors that can lead to other infections and sexually transmitted
diseases. Anal cancer is one of the most common NADCs among HIV-positive patients and is highly
associated with HPV infection. HPV infection is also strongly associated with oral/pharyngeal cancers.
As NADCs are investigated, lifestyle associated risk factors should be considered. However, there is
another key factor in NADC risk among the HIV-infected that should not be ignored—the use of HAART.
Several studies have examined how cancer risk changes before and after HAART became the
standard of care to begin to understand its impact on overall cancer risk. In the Multicenter AIDS Cohort
Study from the pre-HAART time period compared to the HAART time period, anal cancer incidence
increase but other NADCs were statistically unchanged (Seaberg, et al., 2010). In an Italian cohort of HIVinfected patients between 1985 and 2011 there was an overall increase in NADCs after the HAART era
(Franzetti, et al., 2013). This study also reported that age, an AIDS diagnosis, and a nadir CD4 count less
than 200 cells/mm3 were independently associated risk of NADC. In a univariate analysis, homosexual
men were also associated with increased risk. In patients on HAART, risk decreased as current CD4
counts increased. The same trend was true in patients off HAART, although overall incidence rates for
each category of CD4 count level were lower (Franzetti, et al., 2013).
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A large single-center cohort in Europe investigated individual cancer types and their associated
risk with treatment and immunologic related factors (nadir CD4 count, duration of HIV-positivity, HAART
use, and presence of AIDS) in the pre-HAART (up to 1995), early-HAART (1996-2001, and established
HAART period (2002-2007). NADCs overall had an increased incidence in the early and established
HAART time periods. Information on specific cancers are as follows: Anal cancer was significantly higher
in all three time periods compared to the general population. It was associated with nadir CD4 count
less than 200 cells/mm3; Liver cancer was significantly higher than the general population and had
increased incidence in only the established HAART era. No treatment or immunologic factors were
associated with risk; Head and neck cancer tended to show an increase but was not significant and
found unrelated to any treatment or immune factors; Lung cancer saw a significant increase in the early
and established HAART eras. It was associated with prolonged HIV infection, HAART use, and nadir CD4
count less than 200 cells/mm3; Hodgkin’s lymphoma incidence was higher than the general population
and saw an increase in all three study periods. It was associated with HAART use, and specifically use of
a non-nucleoside reverse transcriptase inhibitor (NNRTI) and was the only cancer that was found to be
associated with a specific class of drug. However, this study only examined three types of drug classes:
NNRTIs, nucleoside reverse transcriptase inhibitors (NRTIs), and protease inhibitors (PIs). The other
classes came out around the time of the study and thus would not be in the cohort yet (Powles, et al.,
2009).
A meta-analysis of studies describing risk of cancer in an HIV-infected population found overall
risk of NADCs increased after use of HAART began. Significant risk was found in cancers of the anus,
colorectum, liver, lung, and prostate and Hodgkin’s lymphoma (Cobucci, et al., 2015). In a separate
study, it was concluded that virus-related NADCs were inversely associated with CD4 count measured at
6 months after initiation of HAART, latest CD4 count, and CD4 count-years (a cumulative measure of
immunologic response) indicating a poor CD4 response is associated with risk of a acquiring a virus-
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related NADC (Yanik, et al., Relationship of immunologic response to antiretroviral therapy with nonAIDS defining cancer incidence, 2014).
Thus, it is clear the institution of HAART as the recommended treatment of HIV has had an
impact on cancer risk, and specifically NADCs. In the first decades of HIV, patients did not often survive
to later ages that are most notably associated with cancer risk. It is most often postulated that HAART’s
effect on NADC risk is due to the increase in survival and an aging population (Shiels & Engels, Evolving
epidemiology of HIV-associated malignancies, 2017). A less studied, but suggested hypothesis is an
effect caused directly by prolonged use of HAART (Cobucci, et al., 2015). Finally, it is also imperative to
consider the immune suppression brought on by HAART and the affect this may have on the progression
to cancer after exposure to associated risk factors.

Mortality in the HIV-infected Cancer population
In the U.S., HIV infection has been associated with elevated rates of mortality in NADCs of the
colorectum, pancreas, larynx, lung, melanoma, breast, and prostate. Even after controlling for cancer
stage, mortality was still excess risk of death among HIV-infected persons diagnosed with some NADCs
(Coghill, Shiels, Suneja, & Engels, 2015). Factors that have been found to be associated with an
increased risk of NADC mortality include a lower CD4 cell count, older age (1.60; 95% CI: 1.49-1.72),
being a current or previous smoker (2.89; 95% CI: 1.86-4.48 & 2.01; 95% CI: 1.22-3.32), longer
cumulative exposure to HAART (1.76; 95% CI: 1.25-2.47), and having an active Hepatitis B infection
(1.81; 95% CI: 1.14-2.88) (Data Collection on Adverse Events of Anti-HIV Drugs (D: A: D) Study Group;,
2008). The link between immunosuppression and NADC mortality has been studied but with conflicting
results. One study noted an effect of low CD4 counts and low HAART adherence on all-cause mortality in
HIV-infected patients with lymphoma. Another noted cancer-specific mortality was not affected by HIV
status in patients with Hodgkin’s lymphoma (Coghill, Shiels, Suneja, & Engels, 2015) (Shiels, et al., 2014).
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A third study of patients with a well-controlled HIV infection (as determined by CD4 counts) found that
all-cause mortality was comparable to general population, but this study was not specific to mortality
caused by cancer (Rodger, et al., 2013).
Among a cohort of HIV-infected persons who were treated with HAART for at least 6 months
and had a cancer diagnosis between 1996-2009 highest overall mortality rates were among CNS NHL
(90.6 per 100 person-years), liver (84.3 per 100 person-years), and lung cancer (68.1 per 100 personyears). Patients who were older and had “stave IV equivalent” cancer had the highest overall risk (HR of
1.44 and 2.30, respectively). Those with higher CD4 counts at cancer diagnosis; who had achieved HIVRNA suppression less than 400 copies/ml; had received cancer treatment; and/or had ADCs or infectionrelated NADCs were associated with a lower adjusted HR (Achenbach, et al., 2011).
These studies seem to indicate that immunosuppression and specific types of cancers in HIVinfected persons put them at higher risk for death after a cancer diagnosis. It is important, then, to
understand these risks and how to effectively treat an HIV-infected person with cancer to lower risk for
death.

Gaps in the current research
HAART has increased the lifespan of HIV-infected persons and introduced new concerns that
coincide with this now aging population. More research is needed to better understand chronic disease
comorbidity, like cancer, in the HIV-infected population. There are still many questions about the
complex associations between lifestyle behaviors, HAART, HIV and cancer after an HIV diagnosis. With
1.1 million people living with HIV in the U.S and approximately 38,739 new cases each year, the longterm effects of their treatment and care, especially those related to chronic conditions following proper
management of HIV, are a significant and costly burden on the US healthcare system. Current estimates
suggest the lifetime medical costs for an HIV-infected person at age 35 are $326,500 and 60% of those

31
costs being attributed to ART alone with an aggregate U.S. burden of cost attributed to HIV/AIDS
approximately 10.7 billion higher than non-infected individuals (Ritchwood, Bishu, & Egede, 2017).
Successful treatment using HAART has led to less drug resistance and better control of the virus
and, therefore, HIV-infected patients are now living longer. Life expectancy in HIV-infected patients has
increased, with, for example, a 20-year old patient increasing their life expectancy from 36.1 years to
51.4 years from 2000-2007 (Samji, et al., 2013).
The tradeoff of longer life, though, is the arrival of new complications of living with HIV.
Compared to those living with HIV before HAART, current HIV-infected patients will spend more time on
ART; they will encounter higher levels of exposure to risk factors that pre-dispose one to chronic
diseases; and they will now confront the effects of aging. One important consequence of these new
complications, is the development of other cancers, the NADCs which increased threefold in the HIVinfected population from the pre- to post-HAART era (Shiels, et al., 2011). The cancers most likely to
present in an HIV-infected patient may be related to another virus (cervical and anal cancers related to
HPV; or liver cancer related to Hepatitis B and Hepatitis C infection) or lifestyle factors that occur heavily
in the HIV-infected population (cancers such as liver, lung, or oral/pharyngeal cancers associated with
tobacco and alcohol use). The risk of cancers associated with infections is increased in the HIV-increased
population because of greater prevalence of these infections in this population and their loss of ability
to fend off the infections due to their partially suppressed immune system (Silverberg, et al., 2009).
The time to development of an NADC after ART initiation is 1-10 years (Yanik, et al., 2013), a
somewhat large timeframe in which patient adherence to medication may change or they may
drastically reduce frequency of follow-up visits. Following successful control of an HIV infection will now
require attention to presence of factors that lead to NADCs. However, it is not currently understood
what factors specifically influence the time to development of an NADC; and how risk factors alone or
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combined can affect risk of development of an NADC. This is difficult to study because, while incidence
of an NADC is increasing, it still exists at a relatively small sample size. Additionally, limited data exists
with complete information on cancer and HIV diagnoses to capture reliable information about the
relationship between HIV and an NADC diagnosis.
This dissertation has investigated the factors that contribute to an NADC diagnosis in HIVinfected patients and understand how certain factors affect the time to development of an NADC.
Further, by examining incidence of and mortality due to an NADC diagnosis, clinicians and researchers
can understand the burden in the U.S. of cancers attributed to overcoming an HIV diagnosis. The results
will help clinicians and health experts better understand the changing future of an HIV diagnosis and
what successful treatment of HIV means. Prior hurdles in HIV treatment and care included identifying a
successful antiretroviral regimen to lower viral load to undetectable levels, thus preventing mortality
and AIDS. With advances in HAART, successful management of HIV is more common, leading to
increased longevity of life. Thus, the contribution of this dissertation will be important in guiding
clinicians and public health to be better prepared to manage the new challenges in their care,
specifically attributed to NADCs.

Study Aims
The following aims have been developed for this dissertation study.

Aim 1
Determine NADC burden and mortality in HIV-positive patients receiving HAART compared to the
general U.S. population. This will be done by comparing CNICS to SEER, which will represent the general
population, to understand; (a) Is the observed NADC incidence in the HIV+ population different from the
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expected incidence, as evaluated by the incidence of NADCs in the general population? (b) Is mortality
due to NADCs different in the HIV+ population as compared to HIV-negative general population?

Aim 2
Identify the factors that affect the time to diagnosis of an NADC after initiation of HAART in HIV+
patients in the U.S. This will be done by addressing the following questions: (a) What is the time from
initiation of HAART to diagnosis of an NADC? (b) What are the factors that affect time to diagnosis of an
NADC?

Aim 3
Develop a nomogram and evaluate the risk factors associated with an NADC diagnosis after initiation
of HAART in HIV-positive patients in the U.S. The nomogram predictive model will seek to determine:
(a) What are the key risk factors and do some contribute more weight to the overall risk for an NADC
diagnosis? (b) How does overall risk increase as more or certain risk factors are exhibited by an HIV+
patient?

Source of Data
To accomplish the aims of this dissertation, data from the CFAR Networks of Integrated Clinical
Systems (CNICS) was used. CNICS is an electronic medical records-based network which collects
comprehensive health information from HIV-infected patients as they seek care at one of 8 Center for
AIDS Research (CFAR) medical centers across the U.S. Data is continuously collected from the electronic
medical record throughout care. Data is prospectively collected and includes information on
demographics, diagnosis, laboratory, medication, health care utilization, vital status, patient reported
measures and outcomes (PROs), antiretroviral resistance, and biologic specimens. Data collection was
initiated and available from January 1, 1996.
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Cancer diagnoses are collected as a part of routine care and are verified via standardized
protocol at each site by the CNICS collaborate team. Verification of cancer diagnoses is done in waves
and was recently verified through the end of 2014
CNICS includes information on over 30,000 HIV-infected adults receiving care between January
1996 and present time. At each site incident cases of cancer are verified and information including type,
histology, grade, staging, and treatment is collected. Follow-up frequency of patients is about 3 months
but depends on condition and thus can be more or less often.
CNICS is a large, geographically diverse database of HIV-infected patients. Because the number
of people who have HIV and cancer is relatively small compared to other diseases, having enough study
sample to assess etiology can be difficult. Thus, CNICS offers a unique data source for those
investigating cancer in the HIV-infected. It is one of few in the U.S. that collects cancer information as
well as HIV-treatment and routine care information.

CHAPTER 2: DETERMINING THE BURDEN OF NADCS IN THE U.S. HIVINFECTED POPULATION WHO HAVE INITIATED ART
Introduction
There are currently more than 1.1 million people living with HIV in the U.S. (Centers for Disease
Control and Prevention, 2018). Continuous treatment of HIV with antiretroviral therapy (ART) is
essential to prevent progression to Acquired Immunodeficiency Syndrome (AIDS), reduce mortality, and
reduce risk of other comorbid conditions (Bartlett, 2016). People living with HIV and lacking adequate
treatment with ART are at risk of certain AIDS-defining conditions, which include three cancers, Kaposi’s
sarcoma, non-Hodgkin’s lymphoma, and invasive cervical cancer and are referred to as AIDS-defining
cancers (ADCs) (Shiels, et al., 2011). Recent advances in ART, including the introduction of highly active
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antiretroviral therapy (HAART) in 1996, has led to improved treatment of HIV and increased life
expectancy in people living with HIV. Such advances in treatment have also led to a decrease in rates of
ADCs. However, as rates of ADCs are declining, rates of other cancers, referred to as non-AIDS defining
cancers (NADCs), are now increasing in the HIV-infected population, even among patients receiving
antiretroviral therapy (ART) (Cobucci, et al., 2015). Further, mortality rates associated with NADCs in
HIV-infected patients receiving ART seem to be high (Achenbach, et al., 2011).
Increasing rates of NADCs are largely attributed to increased survival from successful treatment
with ART and an aging HIV population. People living with HIV also tend to exhibit higher prevalence of
other lifestyle factors associated with cancer risk. For example, smoking, a risk factor for lung cancer is
found within 40% of the HIV-infected population, while only 19% of the general population is a smoker
(Lifson, et al., 2010). People living with HIV are also often injection drug users (IDU) which is associated
with Hepatitis B and Hepatitis C infection, and thus associated with liver cancer (Mathers, et al., 2008).
Other factors include alcohol use and risky sexual behaviors that predispose one to STIs, especially HPV
(a risk factor for anal, cervical, and oral cancers) (Patel, et al., 2008) (Silverberg, et al., 2009).
These lifestyle factors coupled increased survival and thus longer use of ART make people living
with HIV a unique population at risk for cancers commonly seen in the general population. Therefore, it
is imperative to investigate the burden and mortality of cancer in people living with HIV in the most
recent years and how it differs from the cancer rates and associated mortality among the general
population. Additionally, beginning to discern the differences in factors associated with cancer risk in
these populations will be important moving forward to adapt cancer screening in people living with HIV
moving forward.
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In this study we will compare the burden of NADCs in an HIV population who have initiated ART
to the general population. Additionally, we describe cancer patterns among those living with HIV by
viral and non-viral associated NADCs and by lifestyle factors associated with cancer risk.

Methods
Study population
This study utilized data from a longitudinal cohort of 32,234 patients within the CFAR Network
of Integrated Clinical Systems (CNICS). CNICS is an electronic medical records based database of HIVinfected patients receiving care at one of 8 Centers for AIDS Research (CFARs) in the U.S. since January
1, 1996. Within CNICS, data is continuously collected from the electronic medical record throughout HIV
care related to demographics, diagnoses, laboratory data, medications, health care utilization, vital
status, and some patient reported outcomes. Cancer diagnoses are verified through standardized
review of medical records and have currently been verified through 2014.

Inclusion/Exclusion Criteria
The population for this study was HIV-positive patients who initiated care at a CNICS clinic
between 1996-2014 and had initiated ART. Patients were excluded if they did not have complete ART
data. Cases of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) were
excluded from case selection due to lack of complete registry information. Cases that occurred within 6
months of the patient’s ART start date and secondary or duplicate NADC diagnosis were excluded.

Covariates
Covariates examined in the study population fell into three categories: demographics, HIV
transmission risk factors and other relevant diagnoses. Demographic included age at ART initiation, age
at CNICS initial visit date, sex, and race/ethnicity (White/Black/Other). HIV risk factors were selfreported by the patient at the CNICS initial visit. Patients reported one to five behaviors that put them
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at risk of HIV: (1) history of a blood transfusion or hemophilia, (2) heterosexual contact with an injection
drug user, hemophiliac, or with an HIV-infected person, (3) injection drug use (IDU), (4) men who have
sex with men (MSM), and (5) other factors which included perinatal contact and working in a health care
setting. Other relevant diagnoses that may be related to HIV risk were assessed recorded in the
electronic medical record if present. These included AIDS-defining illnesses (ADI), HBV, HCV, prior or
current tobacco use, prior or current alcohol use and prior or current drug use,. Drug use included use of
amphetamines, cocaine, hallucinogens, marijuana, opiates, sedative/hypnotic/anxiolytic, or other
unspecified drug use. Those patients with no data for other diagnoses were recorded as ‘no’.

Statistical analysis
Differences between NADC cases and those never having an NADC diagnosis were evaluated
using chi-squared test of independence for categorical variables and two-sample t-test for numeric
variables. In order to account for differences in risk factors that can lead to different cancer sites, these
factors were also compared between patients diagnosed with viral-associated NADCs and nonviralassociated NADCs. Viral NADCs included anal, Hodgkin’s lymphoma, liver, oral/pharyngeal, other viralassociated cancers (penile, vaginal and vulvar). Non-viral NADCs included lung, prostate, breast,
melanoma, colorectal, kidney, and other virus-unrelated cancers (all other sites).
Incidence of NADCs in CNICS was determined by using the selected NADC cases among the total
at risk population in CNICS among adults age 19-84. All-cause mortality in CNICS was determined for
those deaths that occurred after an NADC diagnosis. Rates were age-adjusted using 5-year age groups,
except for the youngest age group which was 19-24 due to few subjects who were 19.
Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were adjusted for
age and were determined for the most common NADC sites while those NADC sites with fewer cases
were grouped by similar etiology. The cancer sites included: anal, Hodgkin’s lymphoma, liver,
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oral/pharyngeal, other viral-associated cancers (penile, vaginal and vulvar), lung, prostate, breast,
melanoma, colorectal, kidney, and other virus-unrelated cancers (all other sites).
The general population used to determine SIRs and SMRs was Surveillance, Epidemiology, and
End Results (SEER) 13 cohort. SEER rates were applied to the at-risk population in CNICS for both
incidence and mortality to estimate expected counts of NADC cases or deaths in CNICS. SIRs and SMRs
were found by taking the observed number of cases divided by the expected number of cases. Those
rates over 1 indicate a count higher than expected in CNICS.
Kaplan-Meier (KM) curves were generated to investigate survival in CNICS and compare
differences across groups. KM curves were made for the total CNICS population compared to those with
an NADC or ADC diagnosis. Time was calculated as time from ART initiation to death or censoring (last
known visit or December 31, 2014; whichever came first). ART start times of 1987 or later were
included. Non-NADC patients were excluded if they did not have at least 6 months of follow-up time
after starting ART. KM curves were also made in a similar manner to compare viral-associated NADCs
and nonviral-associated NADCs.
The analysis was done using SAS software 9.4. The University of Nebraska Medical Center
Institutional Review Board approved this study before its inception (IRB # 655-16-EP).

Results
There were 28,528 patients contributing 80,094,540 person-years in CNICS who had complete
ART information and were considered at-risk for an NADC diagnosis in 1996-2014. Of the 3,233 cancer
diagnoses in CNICS in 1996-2014 with complete ART data, 1,458 were ADCs. After applying all other
inclusion and exclusion criteria, there were 1,023 incident cases of an NADC (Figure 4).

39

Figure 4. Selection total, eligible at-risk population and NADC cases in CNICs

The median age at ART initiation and CNICS initial visit for the total population was 37 years and
39 years, respectively. There were 4,519 (16%) deaths from all causes in CNICS during the study years.
The study population was 81% male, 45% White, and 38% Black. Among the HIV risk factors, MSM
(60%) and heterosexual contact (38%) were the most common. Among the total population the most
relevant other diagnoses were Tobacco Use (53%) drug use (49%). (Table 1.)
Table 1. Descriptive Statistics of NADC cases compared to those not diagnosed with an NADC in CNICS, 1996-2014

Non-NADC
N=27,505

NADC Cases
N=1,023

p-value

*Age at ART initiation
*Age at CNICS initial visit

37 (31-45)
39 (32-46)

42 (36-49.5)
45 (39-52)

<0.0001
<0.0001

Deaths

4,030 (14%)

489 (47%)

<0.0001

Sex
Female
Male

5186 (19%)
22319 (81%)

182 (18%)
841 (82%)

0.39

40
Race/Ethnicity
Black
White
Other**

<0.0001
10427 (38%)
12434 (45%)
4,644 (17%)

459 (45%)
460 (45%)
104 (10%)

HIV Risk Factor
Blood Transfusion
Heterosexual contact
IDU
MSM
Other

472 (2%)
10,447 (38%)
4,741 (17%)
16,536 (60%)
773 (3%)

31 (3%)
413 (40%)
215 (21%)
564 (55%)
22 (2%)

0.0017
0.12
0.0017
0.0014
0.19

Other Relevant Diagnoses
ADI
Hepatitis B
Hepatitis C
Drug use
Tobacco use
Alcohol use

9, 285(34%)
2,484 (9%)
5,189 (19%)
9,637 (35%)
10,407 (38%)
5,176 (19%)

543 (53%)
181 (18%)
288 (28%)
387 (38%)
512 (50%)
274 (27%)

<0.0001
<0.0001
<0.0001
0.066
<0.0001
<0.0001

*Median (IQR)
**Other includes Asian, American Indian/Native American, Multiracial, and Pacific Islander, Hispanic, unknown

When comparing patients in CNICS diagnosed with an NADC to those who were not, nearly all
demographics, HIV risk factors, and other relevant diagnoses differed significantly between the groups.
Among NADC cases the median age at ART initiation was 42 years and the median age at CNICS initial
visit was 45 years compared to those not diagnosed with NADC (37 years and 39 years, respectively)
(p<0.0001). Participants with an NADC were more likely to die compared to participants without an
NADC (47% vs 14%, p<0.0001). The sex distribution among NADCs (82% male) was nearly equal to that
of those not diagnosed with an NADC. Whites represented the majority in both NADC cases (45%) and
non-cases (45%). However, the distribution of blacks and other races/ethnicities were noticeably
different among between groups (NADC cases: 45%, 10%; non-cases: 38% and 17%). Among HIV risk
factors the highest proportion in both groups was MSM, although it was slightly higher in non-cases
(60%) compared to NADC cases (55%) (p=0.0014). NADC cases had a higher percentage of patients who
had a blood transfusion (3%; p=0.0017) and IDU (21%; p=0.0017) compared to non-cases (2% and 17%).
Among NADC cases the most common other relevant diagnoses were ADIs (53%, p<0.0001) and Tobacco
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Use (50%, p<0.0001), which were notably higher proportions compared to non-cases (34% and 38%).
There were no significant differences by sex, heterosexual contact, other HIV risk factors, and drug use.
(Table 1)
When comparing viral associated NADCs to nonviral-associated NADCs non-viral cases were
older with an age at ART initiation 45 vs 40 in viral cases (p<0.0001); and an age at CNICS initiation of 47
compared to 42 on viral cases (p<0.0001). The distribution of sex also differed with there being a much
higher proportion of males with viral cancer (90%) compared to males with non-viral cancers
(77%)(p<0.0001). Heterosexual contact was more common among nonviral cancers (45% vs 33%,
p<0.0001) and MSM was more common among viral cancers (65% vs 49%, p<0.0001). Factors that were
different among the groups, though, not as much as the prior factors included: number of deaths (43%
viral vs 51% nonviral, p=0.009), race/ethnicity (Black 41% vs 48%, White: 46% vs 44%, Other: 13% vs 8%;
p=0.014), blood transfusion (2% vs 4%, p=0.024), IDU (17% vs 23%, p=0.023), ADI (57% vs 50%, p=0.026),
and hepatitis B (21% vs 15%, p=0.013). All other factors were not significantly different between the
groups. (Table 2)
Table 2. Comparison of factors among Viral-associated and non-viral associated NADCs in CNICS, 1996-2014

Viral Cancer
Cases (n=397)

Non-viral Cancer
cases (n=626)

p-value

Age at ART initiation*
Age at CNICS initial visit*

40 (34-47)
42 (36-49)

45 (39-52)
47 (41-54)

<0.0001
<0.0001

Deaths

171 (43%)

322 (51%)

0.009

Sex
Female
Male

40 (10%)
357 (90%)

142 (23%)
484 (77%)

<0.0001

Race/Ethnicity
Black
White
Other*

161 (41%)
184 (46%)
52 (13%)

298 (48%)
276 (44%)
52 (8%)

0.014

42
HIV Risk Factor
Blood Transfusion
Heterosexual contact
IDU
MSM
Other

6 (2%)
130 (33%)
69 (17%)
260 (65%)
10 (3%)

25 (4%)
283 (45%)
146 (23%)
304 (49%)
12 (2%)

0.024
<0.0001
0.023
<0.0001
0.52

Other Relevant Diagnoses
ADI
Hepatitis B
Hepatitis C
Substance use
Tobacco use
Alcohol use

228 (57%)
85 (21%)
120 (30%)
155(39%)
200 (50%)
111 (28%)

315 (50%)
96 (15%)
168 (27%)
232 (37%)
315 (50%)
163 (26%)

0.026
0.013
0.24
0.52
0.99
0.49

*Median (IQR)
**Other includes Asian, American Indian/Native American, Multiracial, and Pacific Islander, Hispanic, unknown

SIRs and SMRs showed higher rates of all cancers and deaths after a cancer diagnosis in HIVinfected patients compared to the general population using SEER data. The overall SIR for primary
NADCs was 9.3 (95% CI: 8.7-9.8); The highest SIRs were among those cancers related to infectious agents
including: anal cancer (312.2; 95% CI: 269.9-361.2), followed by Hodgkin’s Lymphoma (97.5; 95% CI:
78.8-120.8), then liver cancer (30.9; 95% CI 24.5-39.0). Among NADCs not associated with an infectious
etiologic agent, lung cancer had the highest SIR (14.63; 95% CI: 12.2-16.7) followed by kidney cancer
(11.8; 95% CI: 8.9-15.7); and melanoma (6.2; 95% CI: 4.6-8.3). (Table 3)
Table 3. Standardized Incidence and Mortality ratios of NADCs after ART initiation in CNICS 1996-2014

Cancer Site
ALL NADC
Virus-related cancers
Anal
Hodgkin’s Lymphoma

Cases
1023

SIR (95% CI)
9.3 (8.7-9.8)

Deaths
493

SMR (95% CI)
13.7 (12.5-15.0)

181
84

312.2 (269.9-361.2)
97.5 (78.8-120.8)

60
28

347.2 (269.6-447.2)
140.8 (97.2-203.9)

Liver
Oral/Pharyngeal

71
53

30.9 (24.5-39.0)
15.8 (11.4-19.5)

58
21

35.5 (27.4-45.9)
16.7 (10.9-25.6)

Other Infectious
Related

8

15.8 (7.9-31.6)

3

1.5 (0.47-4.6)

Virus-unrelated cancers

43
Lung
Prostate+
Breast++
Melanoma

161
99
42
43

14.3 (12.23- 16.7)
3.6 (3.0-4.4)
1.7 (1.3- 2.3)
6.2 (4.6- 8.3)

134
22
11
19

17.0 (14.3-20.1)
7.4 (4.9-11.3)
2.6 (1.4-4.7)
11.0 (5.7-21.2)

Colorectal
Kidney
Other Non-Infectious
Related

44
47
190

4.1 (3.1-5.6)
11.8 (8.9-15.7)
5.6 (4.9-6.4)

17
15
114

4.9 (3.1-7.9)
14.2 (8.6-23.6)
10.5 (8.7-12.6)

+Prostate
++Breast

cancer SIR/SMR was determined for males only
cancer SIR/SMR was determined for males and females

The overall SMR for primary NADCs was 13.7 (95% CI: 12.5-15.0). he SMRs followed a similar
pattern with the highest overall site-specific SMR being for anal cancer (347.2; 95% CI: 269.6-447.2),
then Hodgkin’s lymphoma (140.8; 95% CI: 97.2-203.9), and liver cancer (35.5; 95% CI: 27.4-45.9).
Among the infection unrelated cancers lung cancer was highest (17.0; 95% CI: 14.3-20.1), followed by
kidney cancer (14.2; 95% CI: 8.6-23.6), and melanoma (11.0; 95% CI: 5.7-21.2). (Table 3)
When comparing survival after ART initiation among NADC cases to those in CNICS not
diagnosed with an NADC, the survival was significantly (p<0.0001) lower for NADC cases compared to
the non-cases, with a median survival of approximately 14 years for NADC cases and 25 years for noncases (Figure 5).
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Figure 5. Time from ART initiation to a death or last day of follow-up. Survival was estimated using the Kaplan-Meier method to
estimate survival in among strata (0=Cancer-free; 1=NADC).

After pulling out ADC cases from the non-cases the median survival of the cancer free
population increased further to nearly 27 years. Interestingly, in the first 13 years after ART initiation
ADC survival was lower compared to NADC cases and cancer-free cases, but as time progressed past 15
years NADC survival became lower than ADC cases. (Figure 6)
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Figure 6. Time from ART initiation to a death or last day of follow-up. Survival was estimated using the Kaplan-Meier method to
estimate survival in among strata (1=Cancer-free; 2=NADC; 3=ADC).

Among NADC cases, viral associated cancers were compared to non-viral associated cancers.
Those with a viral-associated cancers had significantly (P=0.0016) better survival compared to the nonviral associated cancers. (Figure 7 and 8) When survival from NADC diagnosis was examined, median
survival for viral and non-viral cancers was about 2100 days and 1700 days respectively. (Figure 7) When
survival was measured from ART initiation, the difference was slightly less significant between groups
(p=0.011) and median survival for viral and non-viral cancers was about 7000 days and 5000 days
respectively. (Figure 8)

46

Figure 7. Time from NADC diagnosis to a death or last day of follow-up. Survival was estimated using the Kaplan-Meier method
to estimate survival among strata (0=nonviral NADC; 1=viral NADC).
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Figure 8. Time from ART initiation to a death or last day of follow-up. Survival was estimated using the Kaplan-Meier method to
estimate survival in among strata (0=nonviral NADC; 1=viral NADC).

Discussion
This study found the burden of NADCs to be higher among an HIV-infected population receiving
ART compared to a general HIV-uninfected population. HIV-positive patients receiving ART to manage
their infection are at much higher risk of infection-related NADCs and particularly anal cancer, Hodgkin’s
Lymphoma and liver cancer. Malignancies in the oral cavity/pharynx, lung and kidney also seem to be
much more elevated in the HIV-positive population. In addition, mortality after one of these cancer
diagnoses was elevated compared to death in the general population after a cancer diagnoses at one of
these sites.
Differences were found by HIV transmission risk factors such as heterosexual contact, MSM, and
IDU and other relevant diagnoses between NADC cases and non-cases. Other relevant diagnoses such
as AIDS-defining illnesses, hepatitis B, hepatitis C, tobacco use, and alcohol use were most different
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between the groups. When comparing viral and non-viral NADCs, other relevant diagnoses were not as
important, but instead differences in HIV risk factors such as heterosexual contact and MSM stood out.
Survival after ART initiation was lower for those with an NADC diagnosis compared to those who
did not have an NADC diagnosis and among non-viral NADCs compared to viral NADCs. Survival after an
NADC diagnosis is, at first, better compared to an ADC diagnosis. However, at approximately 13 years,
survival is lower for NADCs than ADCs.
Prior studies have shown that NADCs are increasing in the U.S. HIV-infected population and that
NADC rates increased from the pre-HAART era to early-HAART era (Shiels & Engels, 2017) This study
further demonstrates these trends have continued into the current era. In an HIV-cancer match anal
cancer rates showed steady increases at 3% per year during 1996-2010, but reported little to no change
in the same time period for liver, lung, and Hodgkin lymphoma. However, another study supports the
results of this study by concluding a 32-fold elevation in anal cancer, 2-fold increase in lung cancer, 3fold increase in liver cancer and 10-fold increase in Hodgkin lymphoma in a U.S. HIV-infected population
for the years 2006-2010 (Robbins, et al., 2015). This pattern mimics the same found in this study with
the highest elevated incidence in anal cancer, followed by Hodgkin lymphoma, liver cancer, and lung
cancer.
In another study, again rates of anal cancer (69 per 100,000 person years), Hodgkin lymphoma
(58 per 100,000 person years), liver cancer (37 per 100,000 person years), and lung cancer (56 per
100,000 person years) were among the highest rates of individual NADC sites. The same study also
found rates of prostate cancer (54 per 100,000 person years) and breast cancer (128 per 100,000
person-years among females only) to be similarly high (Yanik, et al., 2013). This is similar to the findings
of this study as well. However, the rates of breast cancer appear to be much lower in our study because
we included cases of male breast cancer in the rates.
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A matched cohort study of HIV-infected patients and HIV-uninfected patients showed reduced
mortality after diagnoses of anal, HL, prostate, colorectal, and lung cancer among the HIV-infected
patients, but was only significant for lung and prostate cancer. This study, though had small sample size
and few cancer diagnoses in HIV-infected patients limiting their study power, and only examined
mortality within 5 years (Marcus, et al., 2015). Another study of 14 common cancers in 6 U.S. states
found that HIV was associated with elevated rates of mortality in cancers of the colorectum, pancreas,
larynx, lung, melanoma, breast, and prostate. Even after controlling for cancer stage, mortality was still
higher for HIV-infected persons compared to HIV-uninfected (Coghill, Shiels, Suneja, & Engels, 2015).
A separate study’s findings align with those in our study related to mortality after an NADC
diagnosis. Crude mortality in a study of HIV-infected patients diagnosed with an NADCs between 19962009 was 20.6 per 100 person-years. Highest individual site mortality was among Hodgkin’s lymphoma
(90.6 per 100 person years), liver (84.3 per 100 person years) and lung cancer (68.1 per 100 person
years). Adjusted hazard of death was also lower for those diagnosed with an ADC (0.59; 95% CI: 0.420.81) and infection-related NADC (0.52; 95% CI: 0.34-0.78) compared to infection-unrelated NADCs
(Achenbach, et al., 2011). These findings support the results of this study. Our study showed that in
Kaplan-Meier curves of survival overall survival was actually lower for NADCs than ADCs. When NADCs
were stratified by viral-related status, non-viral associated NADCs had lower survival than viral-related
NADCs.
While this study was able to find burden of NADC supported by previous work, there were some
limitations to this study. First, while the cohort collected data on other relevant diagnoses they were
self-report and in some cases also lab verified. However, the nature in which diagnoses were collected
from the medical records meant that the presence of the other diagnoses was a yes and absence of a
diagnoses was not recorded in the dataset at all. For the study, missing data was meant to imply the
absence of any other diagnoses. We feel this method was reliable, though. Data was abstracted from
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medical records so if they were not a smoker, for example, it would not have been mentioned.
Additionally, the data user guides recommended this interpretation of the “other relevant diagnoses”.
Another limitation of this study was they we were not able to accurately ascertain HPV status.
Due to the majority of the cohort being male, HPV is not typically tested until after an HPV-associated
disease, like anal cancer, is identified. Thus, HPV status and its relation to NADC outcome would be lead
to biased results. By stratifying the NADCs as viral and non-viral related we were able to address other
risk factors that may be more prominent among one group vs the other. Despite the limitations there
were strengths to this study including sample size of NADCs and complete medical record data for ART,
lifestyle factors, and HIV transmission factors. These strengths allowed better understanding of the
population with complete time information to get a better picture of their complete medical history
after ART initiation. Large sample size led to reliable results, more generalizable to other populations.
In conclusion, this study has shown that burden of NADC among HIV-infected is much higher
than the general population, but on trend with findings from other cohorts. Mortality after an NADC
diagnosis is also higher among HIV-infected persons. Finally, this study showed that lifestyle factors and
other illnesses differ among viral-related and non-viral related NADCs, thus showing the importance in
further evaluation of risk factors for NADCs among the U.S. HIV population.
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CHAPTER 3: LIFESTYLE AND IMMUNE FACTORS THAT AFFECT RISK OF A
NON-AIDS DEFNING CANCER AFTER ART INITIATION
Introduction
Advances in treatment of HIV have led to increased life expectancy among people living with
HIV. A now aging HIV-infected population is at risk of comorbid conditions not previously associated
with HIV infection, especially cancer. Non-AIDS defining cancers (NADCs), those cancers not associated
with advancement to AIDS, are increasing in the U.S. HIV-infected population. Biological changes that
occur after initiation of antiretroviral therapy (ART), including immune reconstitution and changes in HIV
replication, changes related to increased longevity of life such as aging and exposure to known
carcinogens, and the high prevalence of established cancer risk factors in HIV-infected populations are
hypothesized to contribute to the observed increase (Yanik, et al., 2013).
The likelihood of being diagnosed with an NADC was found to increase after initiating treatment
with HAART. Yanik et al., (2013) concluded that NADCs become more common after the first year of ART
initiation but may develop greater than 10 years after ART initiation. A study of HIV-infected patients
who had varying ART treatment status found 133 persons diagnosed with an NADC. Factors including
age older than 40 years (odds ratio [OR], 12.2; P < 0.001), Caucasian/non‐Hispanic race (OR, 2.1; P <
0.001), longer duration of HIV infection (OR, 1.2; P < 0.001), and a history of opportunistic infection (OR,
2.5; P < 0.001) were associated with higher risk of NADC (Burgi, et al., 2005). Another study examined
clinical factors’ associated with all cancers in an HIV-infected population who had initiated ART and
found that lower CD4 at ART initiation was associated with increased risk of NADCs related to HPV only
(Yanik, et al., 2013).
Smoking, associated with lung cancer, is prevalent in 40% of the HIV-infected population
compared to 19% in the general population (Kirk et la., 2017). Injection-drug use (IDU) and men who
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have sex with men (MSM) together are attributed to 1 in 10 new HIV cases in the U.S., both of which are
associated with cancer-related infections (HPV, Hepatitis B, and Hepatitis C) (Centers for Disease Control
and Prevention, 2018) (AIDSinfo, 2019) (Singh, Crane, Audsley, & Lewin, 2017) (Kahler, et al., 2015).
Alcohol use, associated with liver cancer and an increase in risky sexual behaviors are prevalent among
HIV-infected. Of the HIV-infected patients in current routine care, 53% reported drinking alcohol in the
preceding month and rates of hazardous drinking among the same group are more than twice the
estimated rates of the general population with reported rates of 8-54% (Hutton, et al., 2013). Risky
sexual behaviors increase risk for acquiring HPV, Hepatitis B (HBV), and Hepatitis C (HCV) and are often
linked to excessive alcohol use. One in three HIV-infected persons who drink alcohol and are taking ART
are more likely to engage in unprotected anal or vaginal intercourse with HIV-uninfected partners
(Kalichman S. , et al., 2013).
There are a multitude of factors that can place an HIV-infected person at risk of developing an
NADC, even with their HIV infection properly managed on ART. It is not understood how these factors,
impact the risk of NADC diagnosis. Research is needed to define the optimal time and modalities for
cancer screening in the HIV+ population (Achenbach, et al., 2011).
There are currently no robust cancer screening and prevention guidelines for the HIV+
population (Yanik, et al., 2013). Identifying the factors that increase risk of an NADC and hasten time to
diagnosis with and NADC can aid in the development of robust cancer screening and prevention
guidelines for the HIV+ population In this study we aim to identify the factors that affect time to
diagnosis of an NADC after initiation of HAART in HIV+ patients in the U.S.
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Methods
Study population
This study utilized data from a longitudinal cohort of 32,234 patients within the CFAR Network
of Integrated Clinical Systems (CNICS). CNICS is an electronic medical record based database of HIV+
patients receiving care at one of 8 Centers for AIDS Research (CFARs) in the U.S. since January 1, 1996.
Within CNICS, data is continuously collected from the electronic medical record throughout HIV care
related to demographics, diagnoses, laboratory data, medications, health care utilization, vital status,
and some patient reported outcomes. Cancer diagnoses are verified through standardized review of
medical records and have currently been verified through 2014.

Inclusion/Exclusion Criteria
The population for this study was HIV-positive patients who initiated care at a CNICS clinic and
initiated ART between 1996-2014. Patients were excluded if they did not have complete ART data,
including a CD4 count within 6 months before or after initiating ART and a viral load measure within 3
months prior to or 9 months after initiating ART. An NADC case was defined as an HIV-positive person
diagnosed with a cancer that is not an AIDS-defining cancer (Kaposi’s sarcoma, non-Hodgkin’s
lymphoma, and cervical cancer). Cases of non-melanoma skin cancers (basal cell carcinoma and
squamous cell carcinoma) were excluded from case selection. Cases that occurred within 6 months of
the patient’s ART start date and secondary or duplicate NADC diagnosis were excluded.

Covariates
The dependent outcomes of interest were a diagnosis with a viral-related NADC or a non-viral
related NADC. Viral cancers included anal, Hodgkin’s lymphoma, liver, oral/pharyngeal, and other
(vaginal, penile, and vulvar). Non-viral cancers included lung, breast, prostate, melanoma, kidney,
colorectal, and other (all other cancers not already grouped). In order to study the associated risk
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factors for either outcome information on demographics, HIV risk factors, other relevant diagnoses, and
laboratory measures were studied. Demographics included age at ART initiation (years), sex
(male/female), and race/ethnicity (White/Black/Other). HIV transmission risk factors were self-reported
by the patient at the CNICS initial visit. Patients reported one to five behaviors that put them at risk of
HIV: (1) history of a blood transfusion or hemophilia, (2) heterosexual contact with an injection drug
user, hemophiliac, or with an HIV-infected person, (3) injection drug use (IDU), (4) men who have sex
with men (MSM), and (5) other factors which included perinatal contact and working in a health care
setting. Other relevant diagnoses were diagnoses that may be related to HIV risk or diagnosis and were
assessed during an HIV-related visit and recorded in the electronic medical record if present. They
include AIDS-defining illnesses (ADI) (such as pneumonia, candidiasis or Mycobacterium), drug use
(amphetamines, cocaine, hallucinogens, marijuana, opiates, sedative/hypnotic/anxiolytic, or other
unspecified drug use), tobacco use. Those patients with no data for other diagnoses were recorded as
not having any other relevant diagnoses. Lab measures included: CD4 count within 6 months before or
after initiating ART, viral load measure within 3 months prior to or 9 months after initiating ART, and
nadir CD4 count, and CD4 change as the difference between CD4 count at ART initiation to last recorded
CD4 count. Hepatitis B and Hepatitis C status was also available. A patient was noted positive for
Hepatitis B if they had positive test result for Hepatitis B surface antigen, Hepatitis B viral DNA, or
Hepatitis B E antigen prior to a cancer diagnosis. A patient was noted positive for Hepatitis C if they had
a positive test result for Hepatitis C RNA or a recorded Hepatitis C genotype prior to a cancer diagnosis.

Statistical Analysis
A descriptive analysis was conducted to compare viral and non-viral related NADCs utilizing chisquare tests for categorical variables and two-sample t-test for numeric variables. Univariate and
multivariate cox regression analyses were used with competing risks for death before a cancer diagnosis
and the alternate NADC subgroup (viral or non-viral). Analyses were conducted for the outcome of all
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NADCs and separately for viral and non-viral etiology. A patient was right-censored at December 31,
2014 (the last year of cancer verification) or their last follow-up appointment, whichever came first.
First, a univariate analysis of the selected variables was completed to identify potential
associations with each NADC type. Then, multivariate models were considered for each the viral and
non-viral NADCs. First, a model containing all covariates that indicated a possible association (p<0.20)
from the univariate analyses. Second, a manual backwards selection starting with covariates indicated
in the univariate analyses. Covariates relating to viral infection (HBV and HCV) were not considered in
the non-viral related cancer models because patients who had a viral-related NADC were considered a
competing risk and censored in the Cox regression.
The analysis was done using SAS software 9.4. The University of Nebraska Medical Center
Institutional Review Board approved this study before its inception (IRB # 655-16-EP).

Results
There were 28,528 patients in CNICS who had complete ART information and were considered
at-risk for NADC diagnosis in 1996-2014. After removing patients with no CD4 and viral load information
at ART initiation, there were 18,029 total subjects and 561 NADC cases. Of the NADC cases, 187 were
diagnosed with a viral related NADC and 374 were diagnosed with a non-viral related NADC (Figure 9).
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Figure 9. Selection of Study population with viral and non-viral NADC diagnoses.

The median age of the study population at ART initiation was 39, while the median age of NADC
cases at ART initiation was 45. The majority of the study population was White (43%), followed by Black
(40%). However, among NADC cases the majority was Black (49%), followed by White (39%). Both
populations consisted of about 80% males. All of the other relevant diagnoses occurred at higher
proportions in NADC cases. Most notable were ADIs in NADC cases compared to the total population
(54% vs. 34%) and tobacco use (51% vs 40%, respectively). Among the reported HIV transmission factors
NADC cases had a higher proportion of risk by blood transfusion (3% vs 1.6%), heterosexual contact
(47% vs 41%), and IDU (20% vs 17%). The study population, though, had a higher proportion of risk by
MSM (59% vs 51%) and other (2.5% vs 2%). Both Hepatitis B and C were more prominent among NADC
cases (11% and 23%) (Table 4).
Table 4. Demographics of the total population and NADC cases in CNICS, 1996-2014

Demographics
Age at ART start
Race

Total
(N=18,029)

NADC
(n=561)

39 (32-46)

45 (39-52)
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White (1)
Black (2)
Other (3)
Sex
Male (1)
Female (2)
Other Relevant Diagnoses
ADI Yes (1)
Drug use Yes(1)
Tobacco Use Yes (1)
Alcohol Use Yes(1)
HIV Transmission Risk Factors
Blood Transfusion (1)
Heterosexual Contact (1)
IDU (1)
MSM (1)
Other (1)
Hepatitis B yes(1)
Hepatitis C yes(1)

7681 (43%)
7244 (40%)
3104 (17%)

218 (39%)
274 (49%)
69 (12%)

14428 (80%)
3601 (20%)

445 (79%)
116 (21%)

6180 (34%)
6570 (36%)
7191 (40%)
3622 (20%)

300 (54%)
225 (40%)
287 (51%)
165 (29%)

286 (1.6%)
7397 (41%)
2994 (17%)
10570 (59%)
451 (2.5%)
976 (6.0%)
2391 (15%)

19 (3%)
263 (47%)
111 (20%)
284 (51%)
11 (2%)
62 (11%)
130 (23%)

When comparing viral and non-viral NADCs some covariates had similar patterns or proportions
between the two groups, including race, CD4 count at ART initiation, and nadir CD4. Drug (41% vs 40%),
tobacco (48% vs 53%), and alcohol (31% vs 29%) use were all similarly proportionate between viral and
non-viral, respectively. However, other covariates exhibited differences between the groups. Age
distribution was similar with both viral and non-viral NADCs being in the 44-80 age groups at ART start.
However, the proportion was much higher among non-viral cases (65% vs 45% in viral NADCs). Males
were much more dominant among the viral NADCs (90% vs 74% in non-viral NADCs); and MSM occurred
more often among viral NADCs (62% vs 45%). Viral NADC cases seemed to have lower CD4 counts right
before cancer diagnosis and were slightly more likely to show a deteriorated CD4 count from ART start
to last CD4 count. Finally, Hepatitis B (18% vs 8%) and Hepatitis C (27% vs 21%) were slightly more
common among viral NADCs compared to non-viral NADCs. (Table 5)
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Table 5. Descriptive Statistics of Viral and Non-viral NADC cases in CNICS, 1996-2014

N=18,029

Time to NADC Diagnosis, years
(Mean, range)
Demographics
Age Categories
11-34 (0)
35-43 (1)
44-80 (2)
Race
White (1)
Black (2)
Other (3)
Sex
Male (1)
Female (2)
Other Relevant Diagnoses
ADI Yes (1)
Drug use Yes(1)
Tobacco Use Yes (1)
Alcohol Use Yes(1)
HIV Transmission Risk Factors
Blood Transfusion (1)
Heterosexual Contact (1)
IDU
MSM
Other
Laboratory Measures
CD4 count at ART start
<200 (0)
200-349 (1)
350-500 (2)
>500 (3)
Nadir CD4
<200 (0)
200-349 (1)
350-500 (2)
>500 (3)
Last CD4 before censor date
<200 (0)
200-349 (1)
350-500 (2)
>500 (3)
Viral Load at ART start

Viral NADC
(n=187)

Nonviral
NADC
(n=374)

p-value

5.5 (0.5-17.9)

6.2 (0.5-18.4)

0.02

40 (21%)
63 (34%)
84 (45%)

27 (7%)
103 (28%)
244 (65%)

<0.0001

71 (38%)
87 (47%)
29 (16%)

147 (39%)
187 (50%)
40 (11%)

0.26

169 (90%)
18 (10%)

276 (74%)
98 (26%)

<0.0001

111 (59%)
76 (41%)
90 (48%)
58 (31%)

189 (51%)
149 (40%)
197 (53%)
107 (29%)

0.05
0.86
0.31
0.56

3 (1.6%)
77 (41%)
32 (17%)
115 (62%)
7 (3.7%)

16 (4.3%)
186 (50%)
79 (21%)
169 (45%)
4 (1.0%)

0.10
0.06
0.26
0.0003
0.03
0.14

104 (56%)
47 25%)
16 (9%)
20 (11%)

189 (51%)
81 (22%)
54 (14%)
50 (13%)

162 (87%)
18 (10%)
6 (3%)
1 (0.5%)

293 (78%)
50 (13%)
20 (5%)
11 (3%)

59 (32%)
57 (31%)
30 (16%)
41 (22%)

89 (24%)
82 (22%)
71 (19%)
132 (35%)

0.07

0.003

0.06

59
<500 (0)
500-50,000 (1)
>50,000 (2)
Hepatitis B yes(1)
Hepatitis C yes(1)
CD4 Change (Tertiles)
T1 (-1727 – 18) (Deteriorated)
T2 (19 – 388)
T3 (389 – 5333) (Improved)

48 (26%)
60 (32%)
79 (42%)
34 (18%)
50 (27%)

74 (20%)
157 (42%)
143 (38%)
28 (8%)
80 (21%)

83 (44%)
73 (39%)
31 (17%)

134 (36%)
135 (36%)
105 (28%)

0.0001
0.16
0.009

Findings from the univariate analyses of all covariates against a viral NADC outcome, age, race,
sex, ADI, alcohol, MSM, CD4 at ART start, nadir CD4, last CD4, viral load at ART, hepatitis B, hepatitis C,
and CD4 change indicated a possible association (P<0.20) and were considered for the multivariate
models. CD4 change was included in the multivariate models, and thus CD4 at ART start and last CD4
were left out to avoid overlap. (Table 6)
In both multivariate models, age at ART initiation between 44-80 years, males, prior ADI, and
prior hepatitis B infection significantly increased a person’s hazard of developing a viral-related NADC;
while a higher nadir CD4 and improved CD4 change decreased the hazard of developing a viral-related
NADC. The final model, Model 2, identified age at ART initiation between 44-80 (2.71; 95% CI: 1.843.98), males (2.16; 95% CI: 1.27-3.68), prior ADI (1.42; 95% CI:1.04-1.93), and Hepatitis B (2.44; 95% CI:
1.98-3.55) increased hazard for a viral-related NADC diagnosis. Improved CD4 change from ART
initiation to last measured CD4 decreased the hazard for a viral NADC diagnosis (0.27; 95% CI: 0.180.41). Having a nadir CD4 of 200-349 cells/ul (0.38; 95% CI: 0.23-0.64) or 350-500 cells/ul (0.32; 95% CI:
0.14-0.74) decreased the hazard of a viral NADC outcome compared to those with a nadir CD4 less than
200 cells/ul. The effect seemed to reduce the higher the nadir CD4 was, with those greater than 500
cells/ul (0.11; 0.02-0.80) still reducing the hazard for a viral-related NADC outcome, but not as much as
the other categories. (Table 6)
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Table 6. Analysis of Factors related to Viral NADCs in CNICS, 1996-2014

Univariate
HR (95% CI)
----

AIC
Demographics
Age Categories
11-34
REF
35-43
1.5 (1.01-2.24) a
44-80
2.7 (1.82-3.88) a
Race
White
REF
Black
1.3 (0.98-1.83) a
Other
1.1 (0.74-1.76)
Sex
Female
REF
Male
2.6 (1.59-4.21) a
Other Relevant Diagnoses
ADI
2.1 (1.6-2.8) a
Drug Use
1.1 (0.8-1.5)
Tobacco Use
1.2 (0.9-1.6)
Alcohol Use
1.5 (1.1-2.0) a
HIV Transmission Risk Factors
Blood Transfusion
0.80 (0.26-2.5)
Heterosexual Contact
0.84 (0.63-1.1)
IDU
0.97 (0.66-1.4)
MSM
1.2 (0.91-1.6) a
Other
1.6 (0.73-3.3)
Laboratory Measures
Nadir CD4
<200
REF
200-349
0.31 (0.19-0.50) a
350-500
0.27 (0.12-0.61) a
>500
0.11 (0.02-0.76) a
Viral Load at ART start
<500
500-50,000
REF
>50,000
0.66 (0.45-0.96) a
0.81 (0.57-1.2)
Hepatitis B
3.0 (2.1-4.4) a
Hepatitis C
1.7 (1.2-2.3) a
CD4 Change
Deteriorated
1.2 (0.89-1.7)
Little/no change
REF
Improved
0.27 (0.18-0.41) a
a

Indicates p<0.20; bp<0.05

Model 1
HR (95% CI)
3161.61

Model 2
HR (95% CI)
3157.79

REF
1.39 (0.93-2.08)
2.60 (1.76-3.83) b

REF
1.44 (0.97-2.15)
2.71 (1.84-3.98) b

REF
1.35 (0.96-1.91)
1.19 (0.77-1.84)

REF
1.37 (0.97-1.93)
1.19 (0.77-1.84)

REF
2.08 (1.22-3.55) b

REF
2.16 (1.27-3.68) b

1.41 (1.03-1.92) b
------1.12 (0.81-1.54)

1.42 (1.04-1.93) b
----------

----

---------1.30 (0.92-1.84)
----

---1.36 (0.96-1.95)
----

REF
0.39 (0.23-0.64) b
0.32 (0.14-0.74) b
0.11 (0.02-0.78) b

REF
0.38 (0.23-0.64) b
0.32 (0.14-0.74) b
0.11 (0.02-0.80) b
----

REF
0.73 (0.50-1.08)
0.88 (0.61-1.28)
2.42 (1.66-3.52) b
1.19 (0.84-1.67)

2.44 (1.68-3.55) b
-----

1.30 (0.95-1.80)
REF
0.28 (0.18-0.42) b

1.32 (0.96-1.82)
REF
0.27 (0.18-0.41) b
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Findings from the univariate analyses of all covariates against non-viral NADCs, age, race, sex,
ADI, tobacco use, alcohol use, blood transfusion, heterosexual contact, IDU, MSM, nadir CD4, hepatitis
C, and CD4 change indicated a possible association (p<0.20) and were considered for the multivariate
models. CD4 change was included in the multivariate models, and thus CD4 at ART start and last CD4
were left out to avoid overlap (Table 7).
Both multivariate models found that age at ART initiation 35-43 and 44-80, tobacco use
significantly increased a person’s hazard of developing a non-viral related NADC; while nadir CD4 200349 cells/ul and 350-500 cells/ul and an improved CD4 change significantly decreased a person’s hazard
of developing a non-viral related NADC. The final model, Model 2, found that age at ART of 35-43 (3.8;
95% CI: 2.50-5.9) and 44-80 (12.8; 95% CI: 8.57-19.1), tobacco use (1.3; 95% CI: 1.07-1.6) significantly
increased a persons’ hazard of a non-viral NADC outcome. Males (0.77; 95% CI: 0.66-0.98), higher nadir
CD4 of 200-349 cells/ul (0.53; 95% CI: 0.39-0.72) and 350-500 cells/ul (0.59; 95% CI: 0.37-0.93) and
improved CD4 change (0.45; 95% CI: 0.35-0.58) significantly decreased a persons’ hazard of a non-viral
NADC diagnosis. (Table 7)
Table 7. Analysis of factors related to non-viral NADCs in CNICS, 1996-2014

Univariate
HR (95% CI)
AIC
Demographics
Age Categories
11-34
REF
35-43
3.62 (2.4-5.5) a
44-80
12.03 (8.1-17.9) a
Race
White
REF
Black
1.4 (1.1-1.7) a
Other
0.79 (0.56-1.1) a
Sex
Female
REF
Male
0.78 (0.62-0.99) a
Other Relevant Diagnoses

Model 1
HR (95% CI)
6183.70

Model 2
HR (95% CI)
6174.79

REF
3.8 (2.5-5.8) b
12.7 (8.5-19.0) b

REF
3.8 (2.50-5.9) b
12.8 (8.57-19.1) b

REF
1.2 (0.92-1.5)
0.87 (0.61-1.2)

REF
1.21 (0.96-1.52)
0.89 (0.62-1.26)

REF
0.78 (0.59-1.0)

REF
0.77 (0.60-0.98) b
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ADI Yes
1.4 (1.2-1.7) a
Drug Use
1.1 (0.89-1.3)
Tobacco Use
1.4 (1.2-1.7) a
Alcohol Use
1.3 (1.03-1.6) a
HIV Transmission Risk Factors
Blood Transfusion
2.2 (1.3-3.6) a
Heterosexual Contact
1.2 (0.96-1.4) a
IDU
1.3 (0.98-1.6) a
MSM
0.63 (0.52-0.78) a
Other
0.43 (0.16-1.1)
Laboratory Measures
Nadir CD4
<200
REF
200-349
0.49 (0.36-0.66) a
350-500
0.52 (0.33-0.82) a
>500
0.70 (0.38-1.3)
Viral Load at ART start
<500
REF
500-50,000
1.1 (0.82-1.4)
>50,000
0.92 (0.32-0.54)
CD4 Change
Deteriorated
1.1 (0.84-1.35)
Little/no change
REF
Improved
0.47 (0.37-0.61) a
a

1.04 (0.84-1.3)

----

1.3 (1.07-1.7) b
1.05 (0.83-1.3)

1.3 (1.07-1.6) b
----

1.5 (0.88-2.4)
0.86 (0.67-1.1)
0.86 (0.63-1.2)
0.86 (0.63-1.2)
-----

1.5 (0.92-2.5)
-------------

REF
0.54 (0.40-0.74) b
0.61 (0.38-0.97) b
0.69 (0.37-1.3) b
-----

REF
0.53 (0.39-0.72) b
0.59 (0.37-0.93) b
0.67 (0.37-1.2)
-----

1.11 (0.87-1.4)
REF
0.45 (0.35-0.58) b

1.1(0.90-1.5)
REF
0.45 (0.35-0.58) b

Indicates p<0.20; bp<0.05

Discussion
Since HAART became standard of care for HIV-infected patients in the U.S. there has been an
increase in NADCs observed in this population (Shiels & Engels, 2017). Factors related to immune
response after HAART initiation, lifestyle factors, and treatment have separately been indicated as
increasing risk of an NADC outcome (Yanik, et al., 2013) (Yanik, et al., 2014) (Burgi, et al., 2005). This
study utilized a time-to-event analysis to adjust for factors from each of those categories in order to
identify the factors that affect the time to a diagnosis of an NADC after initiation of HAART. Among 561
diagnosed NADCs among HIV-infected persons who had initiated ART, older age significantly increased
the hazard of an NADC, while nadir CD4 and CD4 change decreased hazard for both viral and non-viral
NADCs. Initially, all NADCs were assessed in a single model. However, it became clear that this had a
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negative impact on the models’ ability to accurately predict risk factors as the risk factors for viral and
non-viral NADCs differed. Therefore, viral and non-viral NADCs were analyzed separately. Males,
persons with a prior ADI diagnosis, and HBV diagnosis were at increased risk for a viral NADC after
adjusting for all other factors. Females and persons who use tobacco were at increased risk for non-viral
NADCs after adjusting for all other factors.
In both viral and non-viral NADCs older age at ART initiation was a predominant risk factor for
diagnosis. Many prior studies have also documented this relationship. A study of 4,498 HIV-infected
U.S. military beneficiaries reported a hazard ratio of 1.84 (95% CI: 1.44-2.4) for each 10 years of
increasing age (Crum-Cianflone, et al., 2009). A separate study reported age older than 40 increased risk
of NADC in 4,144 HIV-infected individuals (OR: 12.2, p<0.001) (Burgi, et al., 2005). In this study non-viral
NADCs had a hazard ratio of more than double that of viral NADCs among 44-80 year-olds, indicating
older age at ART initiation is even more indicative of a non-viral NADC diagnosis. Similarly, a study
found older age increased risk of an NADC, especially among non-lymphoma, HPV-unrelated NADCs
(Yanik, et al., 2013).
Males were at increased risk of viral related NADCs compared to females, but females were at
increased risk for non-viral related NADCs. The elevated risk of females compared to males in non-viral
related NADCs may be a by-product of the competing risks analysis. As shown, males were more likely to
be diagnosed with a viral NADC, and viral NADC was censored as a competing risk in the analysis for
non-viral NADCs, thus leaving more females at risk of an NADC. While this is possible, we are confident
the nature of the competing risk cox model should mitigate much of this bias and still accurately predict
risk. Some studies do support the plausibility of increased risk for females among non-viral NADCs. A
small study found females to be at higher risk for lung-cancer related mortality, though it was not
significant (Kirk, et al., 2007). Another found males were at increased risk of any NADC (HR: 1.47),
though this changed when skin cancers were removed (HR: 0.66), and again, neither were significant in a
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multivariate analysis. The increased risk for males to be diagnosed with a viral NADC may be explained
by the fact that anal cancer is a viral NADC. Risk for anal cancer has been shown to be elevated among
HIV-infected people, and particularly among MSM (Shiels & Engels, 2017). Anal cancer tends to be the
highest observed cancer for HIV-infected men, while breast, ovarian, and lung cancer tend to be the
highly observed among HIV-infected females (Oliver & Chiao, 2017). This may explain the higher risk
among females for a non-viral NADC in this study.
Factors related to immunosuppression seem to be important in determining risk when other
factors are not considered (Guiguet, et al., 2009). However, this held true in this study when lifestyle
factors and other diagnoses were adjusted for in the multivariate models. Nadir CD4 and CD4 change
were indicative of NADC risk, for both viral and non-viral and were significant in all models. Prior studies
have shown CD4 count at ART initiation and the latest CD4 measure were significant predictors of NADC
risk. In this study, CD4 change was a measure created from these two measures to indicate a change in
immune response of a person. Nadir CD4 is less conclusive with some studies relating it to risk of HPVrelated cancers (D'Souza, et al., 2008) (Patel, et al., 2008) (Crum-Cianflone, et al., 2009), while others
found it less important compared to CD4 at ART (Yanik, et al., 2013).
Smoking was also significantly associated with risk for a non-viral NADC diagnosis. This is
expected considering rates of smoking are much higher among HIV-infected persons (Kirk, et al., 2007).
Lung cancer, a non-viral related NADC, is one of the most common NADCs diagnosed among HIVinfected. It is both attributed to smoking, as well as immunosuppression and chronic inflammation
(Guiguet, et al., 2009). Both smoking and immune suppression were shown to be related to non-viral
NADCs in this study.
There were some limitations to this study. First, while the study population was a large sample
size, the number of NADCs was still somewhat small, especially when considering viral and non-viral
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cancers separately. The sample size made it difficult to ascertain complex relationships between factors
such as IDU, HBV, and HCV and it would have been ideal to examine risk factors for individual cancer
sites. However, important relationships were still able to be investigated and there was ample study
population to conclude the importance of other risk factors. HPV was also not included in this analyses
which may have elucidated important relationship among MSM, viral NADCs, and gender. HPV, though,
is the common risk factor of anal and oral/pharyngeal cancer and transmitted through sexual contact, so
by including gender and MSM as a HIV transmission factor, adequate conclusions can still be drawn.
The study exhibited its strengths, though. First, the availability of data for many HIV-infected
patients allowed for inclusion of many risk factors for NADCs. By including demographics, lifestyle
factors, other diagnoses, and immune response data in a multivariable analysis a more complete
understanding of the interplay of all factors on NADC risk could be examined. Also, this study
population was collected from large multicenter study in diverse geographic areas. Finally, the rigorous
verification of cancer diagnoses complete with medical record data assures minimal misclassification.
In conclusion, among HIV-infected patients who have initiated ART in the U.S. we observed
increased risk for all NADCs for older age, lower nadir CD4 and improved CD4 counts from ART initiation
to last measured CD4. With many important risk factors for each NADC, we concluded different risk
factors for viral NADCs compared non-viral NADCs. Moving forward it will be important to tease apart
the risk factors for subgroups of NADCs or even individual NADCs, if sample size permits. This will lead
toward better screening among HIV-infected persons and more informed cancer prevention efforts.
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CHAPTER 4: NOMOGRAMS FOR PREDICTING INDIVIDUAL RISK OF VIRALAND NON-VIRAL RELATED NON-AIDS DEFINING CANCERS
Introduction
The introduction of highly active anti-retroviral therapy (HAART) in the U.S. in 1996, has
continued decreases in mortality among the HIV-infected population (Palella Jr, et al., 1998) (Cobucci, et
al., 2015). Along with this increase in survival, though, there is an increase in rates of co-morbid
conditions and chronic diseases that typically occur later in life, especially cancer (Patel, et al., 2008).
Cancer has always been a concern for HIV-infected populations. Kaposi’s sarcoma, non-Hodgkin’s
lymphoma, and cervical cancer are associated with deteriorating immune function and progression to
AIDS, and are referred to as AIDS-defining cancers (ADCs). However, with improved treatment, the
incidence of ADCs is decreasing. In the U.S. Kaposi’s Sarcoma rates decreased 60-70% and nonHodgkin’s lymphoma decreased 30-50% in the early HAART era. During 2000-2010, it was estimated
that annual rates of KS decreased by 6%, NHL decreased by 5%, and cervical cancer decreased by 12%
(Shiels, et al., 2011) (Patel, et al., 2008).
The incidence of other cancer types, called non-AIDS defining cancers (NADCs), has increased
nearly threefold since 1996 with cancer trends different from the general population (Shiels, et al.,
2011). This dissertation found that cancers of the anus, liver, lung, oropharyngeal cavity, and Hodgkin’s
lymphoma are NADCs of particular importance in the HIV-infected population likely due to shared risk
factors for these cancers and HIV infection. The HIV-infected population is more likely to smoke
(Petoumenos & Law, 2016) and participate in risky behaviors such as unprotected sex (Kalichman S. , et
al., 2013), alcohol use (Scott-Sheldon, et al., 2013), and injection drug use (IDU) (Centers for Disease
Control and Prevention, 2018) that can be associated with risk of developing certain NADCs.
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Many HIV-infected patients are diagnosed at later cancer stages. Achenbach et al. found that
HIV infected persons who developed NADC were typically diagnosed at a late stage, 25% or more did not
receive treatment and that factors such as poor immune status, failure to suppress HIV-RNA, cancer
stage, and lack of treatment were predictors of mortality after an NADC diagnosis. The authors
concluded HIV-infected patients may require novel cancer prevention and treatment strategies that
incorporate key prognostic factors such as level of HIV-RNA suppression, CD4 cells counts, and cancer
screening at a younger age than the general population (Achenbach, et al., 2011).
There is a need for better screening guidelines and prognostic tools to predict the risk of HIV+
patients developing an NADC. The increase of incidence rates of NADCs in HIV-infected persons has
happened in the last 10-15 years, and scientific literature is limited, especially regarding specific factors
associated with increased risk.
Currently, physicians can draw conclusions about risk of certain cancers based on the
consideration of a single risk factor such smoking status to determine the risk for lung cancer. A tool to
estimate overall risk of development of NADCs in an HIV-infected population that considers multiple risk
factors concurrently does not exist. A nomogram uniquely allows numerous combinations of factors,
setting it apart from traditional prognostic tools used by physicians such as look-up tables or decision
trees. Nomograms can be an accurate and useful tool for providing individualized, evidence-based
estimates of risk of cancer development, and thus is a useful and innovative tool to help clinicians assess
their HIV+ patients specific risk for developing and NADC (Shariat, Karakiewicz, Godoy, & Lerner, 2009).
In this study we will develop and validate a nomogram to predict risk of NADCs in the HIV-infected
population.
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Methods
The steps to construct a nomogram were to define the study population; define the outcome of
interest; identify appropriate covariates; construct the nomogram by selecting the final statistical
model; validate the model utilizing a validation sample; and interpret the final nomogram by
constructing a map of points associated with each covariate.

Study Population
Data from a longitudinal cohort of 32,234 patients within the CFAR Network of Integrated
Clinical Systems (CNICS) was used to construct the nomogram. CNICS is an electronic medical-record
based database of HIV+ patients receiving care at one of 8 Centers for AIDS Research (CFARs) in the U.S.
since January 1, 1996. Within CNICS, data is continuously collected from the electronic medical record
throughout HIV care related to demographics, diagnoses, laboratory data, medications, health care
utilization, vital status, and some patient reported outcomes. Cancer diagnoses are verified through
standardized review of medical records and have currently been verified through 2014.
The study population was HIV-positive patients who initiated care at a CNICS clinic between
1996-2014 and had initiated ART. Patients were excluded if they did not have complete ART data,
including a CD4 count within 6 months before or after initiating ART and a viral load measure within 3
months prior to or 9 months after initiating ART. An NADC case was defined as an HIV-positive person
diagnosed with a cancer that was not an AIDS-defining cancer (Kaposi’s sarcoma, non-Hodgkin’s
lymphoma, and cervical cancer). Cases of non-melanoma skin cancers (basal cell carcinoma and
squamous cell carcinoma) were excluded from case selection due to lack of complete registry
information. Cases that occurred within 6 months of the patient’s ART start date and secondary or
duplicate NADC diagnosis were also excluded.
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Outcome
The primary outcome is development of an NADC in patients receiving ART. Due to differences
in cancer etiology, separate models were constructed for viral-related NADCs and non-viral related
NADCs. Viral cancers included anal, Hodgkin’s lymphoma, liver, oral/pharyngeal, and other (vaginal,
penile, and vulvar). Non-viral cancers included lung, breast, prostate, melanoma, kidney, colorectal, and
other (all other cancers not already grouped)

Covariates
Variables were identified a priori based on literature review and clinical expertise (Table 8).
Table 8. Covariates considered in building a nomogram

Demographics

Other Relevant
Diagnoses

HIV
Transmission
Factors

Laboratory
Measures

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Age (at ART initiation)
Race/ethnicity
Sex
Prior AIDS defining infection (ADI)
Drug use
Smoking
Alcohol use
Blood transfusion
Heterosexual Contact with HIVinfected person
Men who have sex with men (MSM)
Injection Drug Use (IDU)
Other
CD4 count at ART initiation
Nadir CD4
Viral Load at ART initiation
Hepatitis B
Hepatitis C
CD4 Change from ART initiation to
Last CD4 count

•
•
•
•
•
•
•
•

Years & Tertiles
White/Black/Other
Male/Female
Yes/No
Ever/Never
Ever/Never
Ever/Never
Yes/No

•
•
•
•
•
•

Cells/ul (Categorical)
Cells/ul (Categorical)
Copies/ml (Categorical)
Yes/No
Yes/No
Cells/ul (Categorical)

Demographics included age at ART initiation (grouped by tertiles), sex, and race/ethnicity.
Other relevant diagnoses were diagnoses that may be related to HIV risk or diagnosis and were assessed
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during an HIV-related visit and recorded in the electronic medical record if present. They included AIDSdefining illnesses (ADI), prior or current drug use, prior or current tobacco use, and prior or current
alcohol use. Drug use included use of amphetamines, cocaine, hallucinogens, marijuana, opiates,
sedative/hypnotic/anxiolytic, or other unspecified drug use. Those patients with no data for other
diagnoses were recorded as ‘no’. HIV transmission risk factors were self-reported by the patient at the
CNICS initial visit. Patients reported one to five behaviors that put them at risk of HIV: (1) history of a
blood transfusion or hemophilia, (2) heterosexual contact with an injection drug user, hemophiliac, or
with an HIV-infected person, (3) injection drug use (IDU), (4) men who have sex with men (MSM), and
(5) other factors which included perinatal contact and working in a health care setting. Lab measures
included a CD4 count within 6 months before or after initiating ART, nadir CD4 count, and a viral load
measure within 3 months prior to or 9 months after initiating ART. Hepatitis B and Hepatitis C status
were lab verified. A patient was noted positive for Hepatitis B if they had positive test result for
Hepatitis B surface antigen, Hepatitis B viral DNA, or Hepatitis B E antigen prior to a cancer diagnosis. A
patient was noted positive for Hepatitis C if they had a positive test result for Hepatitis C RNA or a
recorded Hepatitis C genotype prior to a cancer diagnosis. A variable, CD4 change, was created as the
difference from CD4 at ART initiation to the last CD4 count taken.

Model Selection
A descriptive analysis was conducted to compare viral and non-viral related NADCs utilizing chisquare tests for categorical variables and two-sample t-test for numeric variables. Univariate and
multivariate cox regression analyses were used with competing risks for death before a cancer diagnosis
and the alternate NADC subgroup (viral or non-viral). Analyses were conducted for the outcome of all
NADCs and separately for viral and nonviral etiology. A patient was right-censored at December 31,
2014 (the last year of cancer verification) or their last follow-up appointment, whichever came first.
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First, a univariate analysis of the selected variables was completed to identify potential
associations with each NADC type. Then a multivariate model was constructed by utilizing a manual
backwards selection starting with covariates indicated in the univariate analyses. Covariates relating to
viral infection (HBV and HCV) were not considered in the non-viral related cancer models because
patients who had a viral-related NADC were considered a competing risk and censoring in the Cox
regression.

Validation
Internal validation was used to validate the nomogram by applying the same model to several
new random resamples within the study population. Validation was addressing by measured the
nomograms discrimination, or predictive accuracy of the model. Discrimination is the ability of the
model to separate patients with different outcomes and is valued by use of the concordance index (cindex) which quantifies the concordance between the predicted values and actual values. Bootstrap
resampling created 1000 validation sample sets and a c-index was obtained from each validation set and
averaged across all sets.

Construct the Nomogram
The nomogram was created by ranking the effect estimates of the covariates in the model. The
highest effect size is given 100 points on a scale. The next predictor is assigned points on the scale
proportional to its effect size compared to the first, and highest, effect size on the scale. Total points
correspond to a predicted probability for each outcome. For this nomogram, 2-year, 10-year, and 19year (the longest follow-up time) predicted probabilities of being diagnosed with viral or non-viral NADC
were included.
The analysis was done using SAS software 9.4. The University of Nebraska Medical Center
Institutional Review Board approved this study before its inception (IRB # 655-16-EP).
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Results
There were 28,528 patients in CNICS who had complete ART information and were considered
at-risk for NADC diagnosis in 1996-2014. After removing patients with no CD4 and viral load information
at ART initiation, there were 18,029 total subjects and 561 NADC cases. Of the NADC cases, 187 (33%)
were diagnosed with a viral related NADC and 374 (66%) were diagnosed with a non-viral related NADC.
The distribution of sex in the NADC population was similar to the total population (80% males
and 20% females). The total population was younger than the NADC population, with a median age of
the study population at ART initiation of 39 years, compared to the median age of NADC cases at ART
initiation of 45 years. NADC cases also differed from the study population by race. The majority of the
study population was White (43%), followed by Black (40%). But NADC cases were Black (49%), followed
by White (39%). All of the other relevant diagnoses (ADI, drug, tobacco, alcohol) occurred at higher
proportions in NADC cases. Most notable were ADIs in NADC cases compared to the total population
(54% vs. 34%) and tobacco use (51% vs 40%, respectively). Among the reported HIV transmission factors
NADC cases had a higher proportion of risk by blood transfusion (3% vs 1.6%), heterosexual contact
(47% vs 41%), and IDU (20% vs 17%). The study population, though, had a higher proportion of risk by
MSM (59% vs 51%) and other (2.5% vs 2%). Both Hepatitis B and C were more prominent among NADC
cases (11% and 23%) compared to the total population (6% and 15%) (Table 8).
Table 9. Demographics of the total population and NADC cases in CNICS, 1996-2014

Demographics
Age at ART start
Race
White (1)
Black (2)
Other (3)
Sex
Male (1)

Total
(N=18,029)

NADC
(n=561)

39 (32-46)

45 (39-52)

7681 (43%)
7244 (40%)
3104 (17%)

218 (39%)
274 (49%)
69 (12%)

14428 (80%)

445 (79%)
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Female (2)
Other Relevant Diagnoses
ADI Yes (1)
Drug use Yes(1)
Tobacco Use Yes (1)
Alcohol Use Yes(1)
HIV Transmission Risk Factors
Blood Transfusion (1)
Heterosexual Contact (1)
IDU (1)
MSM (1)
Other (1)
Hepatitis B yes(1)
Hepatitis C yes(1)

3601 (20%)

116 (21%)

6180 (34%)
6570 (36%)
7191 (40%)
3622 (20%)

300 (54%)
225 (40%)
287 (51%)
165 (29%)

286 (1.6%)
7397 (41%)
2994 (17%)
10570 (59%)
451 (2.5%)
976 (6.0%)
2391 (15%)

19 (3%)
263 (47%)
111 (20%)
284 (51%)
11 (2%)
62 (11%)
130 (23%)

Analysis of covariates associated with an NADC
Viral-related NADCs. Findings from the univariate analyses of all covariates against a viral
NADC outcome identified age, race, sex, ADI, alcohol, MSM, nadir CD4, viral load at ART, hepatitis B,
hepatitis C, and CD4 change as having a possible association (P<0.20) and were therefore considered for
the multivariate models. (Table 9)
From multivariate analyses we concluded age at ART initiation between 44-80 years (2.71; 95%
CI: 1.84-3.98), males (2.16; 95% CI: 1.27-3.68), prior ADI (1.42; 95% CI:1.04-1.93), and Hepatitis B (2.44;
95% CI: 1.98-3.55) significantly increased the hazard for a viral-related NADC diagnosis. Improved CD4
change from ART initiation to last measured CD4 significantly decreased the hazard for a viral NADC
diagnosis (0.27; 95% CI: 0.18-0.41). Having a nadir CD4 of 200-349 cells/ul (0.38; 95% CI: 0.23-0.64) or
350-500 cells/ul (0.32; 95% CI: 0.14-0.74) significantly decreased the hazard of a viral NADC outcome
compared to those with a nadir CD4 less than 200 cells/ul. The effect seemed to lessen the higher the
nadir CD4 was, but even greater than 500 cells/ul (0.11; 0.02-0.80) still reduced the hazard for a viralrelated NADC outcome, but not as much as the other categories.
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Other variables included in the final model that were not significantly associated were age at
ART initiation of 35-43 years (1.44; 95% CI: 0.97-2.15), race (Black (1.37; 95% CI: 0.97-1.93)) and Other
(1.19; 95% CI 0.77-1.84)); MSM (1.30; 95% CI: 0.92-1.84); and a deteriorated CD4 change (1.32; 95% CI:
0.96-1.82). (Table 9).
Conclusions from clinical knowledge and cox regression analysis lead to the final decision to
include all covariates, except MSM in the nomogram for viral related NADCs. The study population
includes females and the nomogram is intended for use in both sexes,
Table 10. Factors related to a Viral-related NADC outcome in CNICS, 1996-2014

Univariate
HR (95% CI)
Demographics
Age Categories
11-34
REF
35-43
1.5 (1.01-2.24) a
44-80
2.7 (1.82-3.88) a
Race
White
REF
Black
1.3 (0.98-1.83) a
Other
1.1 (0.74-1.76)
Sex
Female
REF
Male
2.6 (1.59-4.21) a
Other Relevant Diagnoses
ADI
2.1 (1.6-2.8) a
Drug Use
1.1 (0.8-1.5)
Tobacco Use
1.2 (0.9-1.6)
Alcohol Use
1.5 (1.1-2.0) a
HIV Transmission Risk Factors
Blood Transfusion
0.80 (0.26-2.5)
Heterosexual Contact 0.84 (0.63-1.1)
IDU
0.97 (0.66-1.4)
MSM
1.2 (0.91-1.6) a
Other
1.6 (0.73-3.3)
Laboratory Measures
Nadir CD4
<200
REF
200-349
0.31 (0.19-0.50) a

Multivariate
HR (95% CI)

REF
1.44 (0.97-2.15)
2.71 (1.84-3.98) b
REF
1.37 (0.97-1.93)
1.19 (0.77-1.84)
REF
2.16 (1.27-3.68) b
1.42 (1.04-1.93) b
------------------1.30 (0.92-1.84)
----

REF
0.38 (0.23-0.64) b
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350-500
>500
Viral Load at ART
start
<500
500-50,000
>50,000
Hepatitis B
Hepatitis C
CD4 Change
Deteriorated
Little/no change
Improved
a
p<0.20; bp<0.05

0.27 (0.12-0.61) a
0.11 (0.02-0.76) a

0.32 (0.14-0.74) b
0.11 (0.02-0.80) b
----

REF
0.66 (0.45-0.96) a
0.81 (0.57-1.2)
3.0 (2.1-4.4) a
1.7 (1.2-2.3) a

2.44 (1.68-3.55) b
-----

1.2 (0.89-1.7)
REF
0.27 (0.18-0.41) a

1.32 (0.96-1.82)
REF
0.27 (0.18-0.41) b

Non-viral NADC outcome. Findings from the univariate analyses of all covariates against a nonviral NADC outcome identified age, race, sex, ADI, tobacco use, alcohol use, blood transfusion,
heterosexual contact, IDU, MSM, nadir CD4, hepatitis C, and CD4 change as having a possible association
(p<0.20) and were considered for the multivariate models. (Table 10).
Multivariate analyses concluded that age at ART of 35-43 (3.8; 95% CI: 2.50-5.9) and 44-80 (12.8;
95% CI: 8.57-19.1) and tobacco use (1.3; 95% CI: 1.07-1.6) significantly increased a person’s hazard of a
non-viral NADC outcome. Males (0.77; 95% CI: 0.66-0.98), higher nadir CD4 of 200-349 cells/ul (0.53;
95% CI: 0.39-0.72) and 350-500 cells/ul (0.59; 95% CI: 0.37-0.93) and improved CD4 change (0.45; 95%
CI: 0.35-0.58) significantly decreased a persons’ hazard of a non-viral NADC diagnosis. (Table 10)
Other variables included in the final multivariate analyses that were not significantly associated
were race of Black (1.21; 95% CI: 0.96-1.52), Other races (0.89; 95% CI: 0.62-1.26), Blood transfusion as
the patient’s HIV transmission factor (1.5; 95% CI: 0.92-2.5), nadir CD4 >500 cells/ul (0.67; 95% CI: 0.371.2), and a deteriorated CD4 change (1.1; 95% CI: 0.90-1.5).
Conclusions from clinical knowledge and cox regression analysis lead to the final decision to
include all covariates in the nomogram for non-viral related NADCs.
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Table 11. Analysis of factors related to a non-viral related NADCs in CNICS 1996-2014

Univariate
HR (95% CI)
AIC
Demographics
Age Categories
11-34
REF
a
35-43
.62 (2.4-5.5) a
44-80
12.03 (8.1-17.9) a
Race
White
REF
Black
1.4 (1.1-1.7) a
a
Other
.79 (0.56-1.1) a
Sex
Female
REF
Male
0.78 (0.62-0.99) a
Other Relevant Diagnoses
ADI Yes
1.4 (1.2-1.7) a
Drug Use
1.1 (0.89-1.3)
Tobacco Use Yes
1.4 (1.2-1.7) a
Alcohol Use Yes
1.3 (1.03-1.6) a
HIV Transmission Risk Factors
Blood Transfusion
2.2 (1.3-3.6) a
Heterosexual Contact 1.2 (0.96-1.4) a
IDU
1.3 (0.98-1.6) a
MSM
0.63 (0.52-0.78) a
Other
0.43 (0.16-1.1)
Laboratory Measures
Nadir CD4
<200
REF
200-349
0.49 (0.36-0.66) a
350-500
0.52 (0.33-0.82) a
>500
0.70 (0.38-1.3) a
Viral Load at ART
start
REF
<500
1.1 (0.82-1.4)
500-50,000
0.92 (0.32-0.54)
>50,000
CD4 Change
Deteriorated
1.1 (0.84-1.35)
Little/no change
REF
Improved
0.47 (0.37-0.61) a
a
Indicates p<0.20; bp<0.05

Multivariate
HR (95% CI)
6174.79

REF
3.8 (2.50-5.9) b
12.8 (8.57-19.1) b
REF
1.21 (0.96-1.52)
0.89 (0.62-1.26)
REF
0.77 (0.60-0.98) b
---1.3 (1.07-1.6) b
---1.5 (0.92-2.5)
-------------

REF
0.53 (0.39-0.72) b
0.59 (0.37-0.93) b
0.67 (0.37-1.2)
-----

1.1(0.90-1.5)
REF
0.45 (0.35-0.58) b

77

Nomograms
The nomogram created to predict a viral NADC outcome and a non-viral NADC outcome
separately using the covariates identified from the multivariate Cox regression models are seen in
Figures 10 and 11. The total points for the viral-related NADC nomogram is 325 and associated with a 2year probability of diagnosis of 0.025. Further 10-year and 19-year probabilities for a person
accumulating 325 points are 0.191 and 0.427, respectively (Figure 10). The total points for the non-viral
related nomogram is 223 associated with a 2-year probability of a non-viral NADC diagnosis of 0.039
(Figure 11). The probabilities for 10-year and 19-year diagnoses of an NADC are 0.310 and 0.757,
respectively, for accumulating 223 points.

Figure 10. The nomogram for viral NADCs. Nadir CD4 and CD4 change is measured in cells/ul and age is age at ART initiation in
years.
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Figure 11. The nomogram for non-viral NADCs. Nadir CD4 and CD4 change is measured in cells/ul and age is age at ART
initiation in years.

Validation resampling of 1000 samples found a concordance index of 0.466 (+0.016) for viralrelated NADCs. Resample of 1000 samples for the non-viral related NADC nomogram found a c-index of
0.497 (+0.009).

Discussion
This study included 28,525 HIV-infected people who had initiated ART. Demographic, lifestyle,
and immune factors were considered in analysis of their risk for developing an NADC. We constructed a
predictive nomogram for viral-related NADCs and non-viral NADCs in order to estimate risk of
developing an NADC in an individual HIV-infected patient who exhibits one or more associated risk
factors for an NADC, especially an individual assessment of risk. Further, the nomogram was validated
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to assess its ability to accurately predict the risk of developing a viral-related or non-viral related NADC
and found that the prediction ability was average.
Nomograms effectively rank the covariates of a model and map the associated predicted
probability of an outcome. This graphical interface makes it easy to visualize associations between
factors including which are most important and less important in determining risk. In the nomogram for
viral-related NADCs, factors related to immune response including Nadir CD4 and CD4 change were
most important in predicting risk. Age, sex, and prior HBV infection were next, all with similar effect
size. Finally, ADI and race were also included, but with the smallest effect size towards overall risk of
developing a viral NADC.
Factors predicting risk of a non-viral NADC followed a different trend, though. The single most
important risk factor was age, followed by CD4 change and nadir CD4 which had less than half the effect
size as age on the overall risk. Nadir CD4 followed interesting pattern. Like with viral-related NADCs, a
nadir CD4 <200 cells/ul was associated with the highest risk for a non-viral related NADC. However, the
next highest risk was associated with a nadir CD4 >500 cells/ul, then 350-500 cells/ul. Nadir CD4 counts
of 200-349 cells/ul had the small risk. However, the effect sizes were so small and so close that it can
likely be concluded that a nadir CD4 counts >200 cells/ul carry a similar, more protective association
with non-viral related NADCs. Blood transfusion as an HIV transmission factor, race, HCV infection,
tobacco use, and sex were the remaining important risk factors, all with similar and small effect sizes.
It was determined through validation that the nomogram had average prediction capabilities.
With a c-index around 0.50, the nomogram’s ability to predict a person’s viral or non-viral NADC
outcome is about 50%. Ideally, a good nomogram will have a c-index greater than 0.70, therefore the
nomograms for viral and non-viral NADCs built in this study are not ideal predictive tools in this
population. We have a few potential reasons why the nomogram has a low c-index. First, number of
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total NADCs in the study population was 561, representing only 2% of the study population, making it a
somewhat infrequent occurrence. Second, several covariates were investigated that individually are
associated with NADC risk, but also likely interact with each other. Cancer and HIV themselves are
diseases with complex biology and sets of risk factors, to disentangle all of the potential predictors
associated with each may require larger power than available in this study population. Third, we
created viral and non-viral sub-groups of NADCs to reflect differences in risk factors. However, several
cancer sites with unique risk factors are still within the groups. It is likely a predictive tool, such as a
nomogram, is not the best means to predict risk in this scenario and may be more appropriate to
identify a specific cancer, such as anal cancer, instead of a group of cancers (viral or non-viral). Other
nomograms have investigated more specific disease outcomes such as gastric cancer-specific survival
after resection (Kattan, Karpeh, Mazumdar, & Brennan, 2003) or progression to oral/pharyngeal cancer
in HPV+ and HPV- patients (Larsen, et al., 2016). The latter of which investigated only clinical and tumor
characteristics as covariates. It may have been too vague to build a nomogram for a group of unique
diseases with several categories of risk factors.
Even with the limitations to the nomograms built in this study, we were still able to learn more
about the importance of each covariate in relation to each other for viral- and non-viral related NADCs.
By knowing which covariates best predict an NADC outcome, screening guidelines can be improved. In
viral NADCs we found that immune response was most predictive, followed by age. In non-viral NADCs,
it was clear from effect size that age, far and above, was the most predictive. These findings can still
assist in discerning which sub-group of NADC a patient may be at risk for in their initial HIV care visits.
In conclusion, while the nomograms in this study have begun to identify key risk factors for
NADC risk, going forward it will be important to begin to investigate specific NADC sites in HIV-infected
populations. With this research we can begin to create much more effective predictive tools to address
risk of NADCs in the HIV-infected population.
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Chapter 5: Discussion
Summary of Current Research
HIV is believed to have started circulating in humans as early as the 1920’s (AIDS.gov, 2019).
However, the HIV and AIDS epidemic as we know it today began in 1981 when five young, previously
health gay men in Los Angeles were diagnosed with a rare lung infection called Pneumocytstis carinii and
reports of healthy gay men in New York were diagnosed with an unusually aggressive cancer called
Kaposi’s Sarcoma (AVERT, 2018). At the beginning of the epidemic, the lifespan of an HIV-infected
person was around 30 years. Scientific advances in our understanding of HIV, including the
development of antiretroviral drugs, have substantially increased survival and people with access to
treatment now can live long and healthy lives with HIV. Currently, approximately 1.1 million people are
living with HIV in the U.S. (Centers for Disease Control and Prevention, 2018)with a life expectancy of 70
years (Shiels, et al., 2018).
HIV and cancer have always been strongly linked. Chronic HIV infection left untreated leads to
Acquired Immune Deficiency Syndrome (AIDS), and the diagnosis of some cancers, known as AIDSdefining cancers (ADCs) that include: Kaposi’s sarcoma (KS), non-Hodgkin’s lymphoma (NHL), and
invasive cervical cancer (ICC) is an indicator of AIDS.
Strict adherence to highly active anti-retroviral therapy (HAART), the current standard treatment
for HIV and prevention of AIDS, can increase the lifespan of HIV-positive patients by approximately 20
years, and prevent the development of AIDS (Samji, et al., 2013) (Shiels, et al., 2018). However, longer
life expectancy leaves a patient susceptible to the effects of aging, exposure to high risk behaviors, and
long-term exposure to HAART. This places the HIV+ patients at increased risk for other cancers, referred
to as non-AIDS defining cancers (NADCs).
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Recent studies indicate that NADC rates are increasing among HIV-infected persons (Yanik, et
al., 2013) (Shiels, et al., 2011). Investigation of the factors associated with this increase have been
limited and with mixed results (Burgi, et al., 2005) (Yanik, et al., 2013) (D'Souza, et al., 2008) (CrumCianflone, et al., 2009). The lack of research in this area is due in part, to the relatively few longitudinal
data sources in the U.S. that completely capture both HIV and cancer data. A research gap also exists to
understand the scope of NADC burden and the factors associated with an NADC outcome among HIV+
patients receiving routine care. The overarching objective of this dissertation is to investigate the
burden of NADCS among HIV+ in the U.S. and the factors leading to a diagnosis of an NADC in persons
receiving antiretroviral treatment. Our hypothesis is that the burden of NADCs is higher among the HIV+
population compared to that of the general population; and that a combination of several factors
including treatment, immune function, and risky lifestyle factors all contribute to the development of
NADCs in the HIV+ population.
We utilized data from the CFAR Network of Integrated Clinical Systems (CNICS), an electronic
medical record based database of HIV+ patients receiving care at one of 8 Centers for AIDS Research in
the U.S. CNICS contains comprehensive longitudinal, integrated health data which includes:
demographics, clinical diagnosis, laboratory, medications, health care utilization, vital status, patient
reported measures and outcomes, antiretroviral resistance, and biologic specimens for each patient. In
addition, CNICS maintains verified cancer diagnosis data making it a valuable data source to investigate
NADC burden in an HIV+ population.
In Specific Aim 1, we found the burden of NADCs is much higher in persons infected with HIV
and receiving treatment compared to the general population. HIV-positive patients receiving ART to
manage their infection are at much higher risk of cancers including anal cancer (SIR: 312.2), Hodgkin’s
Lymphoma (SIR: 97.5) liver cancer (SIR: 30.9), cancer of the oral cavity/pharynx (SIR: 15.8) and lung (SIR:
14.3). Mortality following a cancer diagnosis is also elevated compared to the general population after a
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cancer diagnosis at one of these sites. For example SMR for anal cancer are 347.2, for Hodgkin’s
lymphoma was 140.8, and for liver cancer was 35.5. In our study population there were survival was
lower among those who had an NADC diagnosis compared to those who did not; and among NADCs not
related to a virus compared to NADC cases that were. After an NADC diagnosis the survival among cases
drops quickly in the years following diagnoses but then steadies.
The time from ART initiation to NADC diagnoses varied with an average of 5.5 years after
initiation of ART for viral NADCs, an average of 6.2 years for non-viral NADCs and some NADCS nearly 20
years after initiation ART. In Specific Aim 2, we examined the factors associated with time to risk for
viral-related NADC diagnoses and a non-viral related NADC diagnoses. In both viral and non-viral NADCs
older age was a predominant risk factor for diagnosis (Viral HR: 2.71; Non-viral HR: 12.8). Increased risk
for a viral NADC was also associated with being Male (HR: 2.16), persons with a prior ADI diagnosis (HR:
1.42, 95% CI 1.04-1.93), and an HBV diagnosis (HR: 2.44) after adjusting for all other factors. Increased
risk for non-viral related NADCs was associated with being female (HR: 1.29) and tobacco use (HR: 1.33)
after adjusting for all other factors. In both viral and non-viral related NADCs the following factors had a
protective effect for diagnoses of an NADC: nadir CD4 counts >200 cells/ul; and little/no change or
improvement in the CD4 count from ART initiation to the last measured CD4 count (compared to those
with deteriorated count).
Finally, in Specific Aim 3 we constructed and validated a nomogram to predict risk of a viralrelated NADC and non-viral related NADC. The predictive accuracy for the nomograms was 50% for both
NADC sub-groups which is not ideal. However, the nomogram is still useful to visualize the association
between predictors and ascertaining the level of importance of each factor in predicting risk. Viralrelated NADCs were best predicted by poor immune response factors (nadir CD4 and CD4 change), while
non-viral related NADCs were best predicted by older age.
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Implications of Current Research
Previous work has demonstrated the increasing incidence of NADCs among the HIV-infected
population in the U.S. (Shiels, et al., 2011). Older age and immune response after ART initiation have
also been found to be associated with NADC risk (Shiels, et al., 2011) (Yanik, et al., 2014). Older age is
the single biggest risk factor for cancer risk in the general population. . A quarter of all new cancer
cases in the general population are diagnosed between the ages of 65-74 years. Screenings for various
cancers, breast, prostate, and colon cancer are recommended to start around the age of 50 years
(National Cancer Institute, 2015).
HIV-infected persons are living longer and are at increased risk for cancer. Cancer screening
recommendations for the general population need to be reconsidered for the HIV+ population. We
found that older age at ART initiation is a risk factor for NADCs, but increased risk for cancer in the HIV
infected population is still much younger than the general population. Risk for both viral and non-viral
related NADCs increased most for those age 44 and older at ART initiation.
Poor Immune response is also associated with increased risk of NADC. Previous studies have
shown that low CD4 counts were associated with HPV-related cancers (Yanik, et al., 2013) and poor CD4
response was strongly associated with viral-related NADCs, but not non-viral related NADCs (Yanik, et
al., 2014). We noted the importance of immune response factors in predicting risk for a viral-related
NADC, and in non-viral related NADCs. CD4 counts are measured early and often in HIV-infected
patients and are indicators of extent of HIV infection. They are among the first measures taken at HIV
diagnosis and monitored closely in persons receiving ART (AIDSinfo, 2019). For HIV-infected persons
receiving care, CD4 counts are closely monitored and therefore may make assessment of immune
response an easy and quick screening indicator for cancer. We found patients with low immune
response was a predictor for an NADC.
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We found that lifestyle factors such as smoking, alcohol use, or MSM were not as strong
predictors of risk as age and immune response factors in our nomogram. Of the lifestyle factors that we
explored (list here), chronic HBV infection, and ADI were predictive factors for viral-related NADCs. This
was expected as chronic HBV infection is a risk factor for liver cancer and many of the ADIs include
infections. Additionally, the predominant cancer site among viral NADCs was anal cancer. Anal cancer is
strongly linked to HPV and it is most common among MSM. MSM was found to be marginally associated
with a viral NADC outcome but was not significant in the multivariate analyses. There are several
reasons that may explain lack of significance. First, females were included in the study population so
MSM was, by definition, not a risk factor for 20% of the study population. Second, in CNICS, MSM was
addressed only at the initial intake exam and in the context of HIV transmission factors and may not be
accurate Finally, information was not available on use of condoms or safe sex practices, which are
extremely relevant in increasing risk of HPV transmission for anal cancer.
The inclusion of chronic HBV infection and ADI in the models, and not MSM or IDU, indicate a
patient’s history of lab verified infection may be a more valid measure than self-report of lifestyle
factors. Current guidelines for HIV care recommend screening for HCV and HBV at the initial
appointment for HIV care, and HPV is recommended if a patient indicates practices that would lead to
its transmission (i.e. MSM or risky sexual behaviors). We’ve shown this information can be used to
identify an HIV persons’ risk for a viral NADC.
There were also some lifestyle factors that predicted non-viral NADCs, but none were as
important as age and immune response. Smoking was a key risk factor, which was expected due to the
strong association between smoking and cancer and the fact that the predominant non-viral NADC was
lung cancer. It has been suggested that reduced immune response in HIV infected persons further
exacerbates the effect of smoking on the lung and, thus, increases risk for lung cancer (Shiels & Engels,
2017). This agrees with our findings that show reduced immune response and tobacco use a predictor
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for non-viral NADC. We may deduce that not only is it important to assess tobacco use among HIVinfected persons, but it is essential to look at tobacco use AND immune response together. The
presence of high tobacco use and low immune response factors could inflate a persons’ risk for a nonviral NADC. We have established that known risk factors, such as smoking, are predictors for NADC,
however extra consideration of these factors is needed in HIV-infected persons, especially due to their
lowered immune function.

Suggested Future Research
The studies we conducted expanded on the current literature relating to risk for an NADC
outcome, and also identified areas that need further investigation. First, and foremost, we highlighted
the need to study individual NADC sites in HIV-infected populations. We discovered the importance of
separating viral and non-viral related NADCs in order to disentangle the various predictors of disease.
Based on differences in risk factors for specific cancers, more research is needed to investigate specific
cancer sites. We were unable to investigate specific cancer site due to problems with low sample size.
Study aim 1 identified the burden specifically attributed to anal cancer, Hodgkin’s lymphoma, liver
cancer, lung cancer, and prostate cancer. As these seem to be rising in the HIV-infected population they
may be of the most important to study first, but also the most accessible to study given the number of
diagnoses.
It is not fully understood how the interplay other viruses and HIV affect risk for viral NADCs.
The ability to fight infection relies on an adequate immune response and it has been shown that
reduced immune response increases risk for an NADC (Yanik, et al., 2014). Reduced immune response
and a pre-existing viral infection may further intensify risk of an NADC. Future research should
investigate this link, particularly with anal cancer, liver cancer, and Hodgkin’s lymphoma.
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A better understanding of the role of lifestyle factors on NADCs is necessary, but difficult in the
HIV-infected population. Much is known about the incidence of smoking, IDU, and MSM among HIVinfected persons. However, there are many intermediate factors that determine if an IDU, for example,
will acquire an HBV or HCV infection. The use of clean needles or understanding other viral status can
inhibit the risk of acquiring the infection that leads to cancer. Another example, Men who have sex with
men, are at increased risk of HPV, but have less risk if safe sex practices are utilized. Understanding a
partner’s infection status for both males and females can also decrease risk of HPV infection. These
intermediate factors should be better understood in HIV-infected persons to have more complete
understanding of their true cancer risk. To avoid bias related to recall, the ideal future research would
be a thorough survey in a longitudinal cohort. In regard to CNICS, questions pertaining to these factors
could be asked at each visit throughout care.
Finally, we did not delve into the ART treatment regimen data in great detail. Due to the
longevity of a persons’ time on ART it is reasonable to hypothesize that ART itself is a risk factor cancer.
Cancer is a disease of mutated and defective cells that cause uncontrolled growth of the cells. HIV is a
retrovirus that inserts itself into the DNA of its host and ART stops the replication of HIV. It is therefore
plausible that ART has a direct effect on the cell itself that may be related to cancer risk. Current
literature has found mixed results relating ART to NADC risk specifically. Powles et al., found no
association between ART use and risk of anal cancer, but Chao et al. found the opposite, particularly
related to therapy including protease inhibitors. The same study also identified a decreased rate of
prostate cancer with long-term ART (Chao, et al., 2012). All other results were inconclusive in relation to
ART and NADC risk. This was a record-linked cohort study that examined duration of ART, therapy class,
and specific cancer sites by linking SEER records to an HIV population in California. To better address this
association it would be ideal to utilize complete medical records in place of a data-linkage system and
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CNICS could be ideal for this in future studies. Laboratory and genetic epidemiology studies would be
ideal to address the association between cancer and ART and a cellular level.

Limitations
We utilized data previously collected through an ongoing medical records based cohort of HIVinfected persons. The utilization of secondary data analysis can be cost- and time- effective, but there
are inherent restrictions. The research questions had to be limited to the data that was previously
collected. The data on lifestyle factors was based on self-report and did not allow for in depth study of
specific behaviors. Alcohol and drug use, for example did not include the duration, quantity or type of
drugs, but rather just indicated any prior or current use. Risky sexual behaviors, which are extremely
relevant in an HIV-infected population were not able to be addressed.
MSM, IDU, heterosexual contact with an HIV-infected person, and blood transfusion were
included in the analyses as proxies for cancer risk. However, these were assessed one time at the initial
intake visit and recorded only if a patient answered “Yes”. First, in this scenario it is reasonable to
assume information bias. Care is just being established and a newly diagnosed HIV-infected may feel
ashamed and hide this information from their physician. Second, no follow-up information was included
to determine the degree to which they practiced these factors. For example, a person who said “yes” to
IDU may be a one-time user, 5-time user, or a user for 10 years. Last, it may be useful to know if the
practice continued well before or long after their HIV diagnoses. Future studies should gather more
information on these factors in order to better understand the history of use.
ART success is greatly reliant on regular, everyday consumption, or regular adherence to the
prescribed therapy. ART adherence was not something that could be measured through CNICS. In any
study, this is a difficult to measure factor, but especially in a cohort with data from medical records.
Data was available marking start and stop dates of medications, but with no indication of regular use of
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the medication adherence could not be fully ascertained. ART could be measured through prescription
refills, but it is common for patients to refill and not take the medications. Medications may also be
counted at care visits, but to avoid shame a patient could dispose of unused medication. Studies that
seek to address adherence would likely need to measure it in several capacities, including patient
survey, pharmacy refill counts, and pill counts.

Conclusions
In conclusion the studies completed for this dissertation have provided insights into new
findings related to NADCs among HIV-infected persons. First, in study aim 1, we showed that the
burden of NADC is higher than the general population. Previous studies have found similar results, but
an unexpected finding of our results was just how high the burden was among HIV-infected persons
compared to the general population. Second, in study aim 2, many well understood risk factors for
cancer such as older age and smoking were analyzed along with factors specific to the HIV-infected
population (i.e. immune response after ART). Findings from this study found distinct risk factors for viral
and non-viral associated NADCs with older age, prior ADI, and HBV predictors of viral NADCs; and older
age and smoking predictors for non-viral NADCs. Further, in both a higher nadir CD4 and an improved
change in CD4 since ART initiation were protective factors. Finally, in study aim 3, the nomogram
showed the importance of some risk factors over others. For viral NADCs, immune response related to
nadir CD4 and CD4 change were the most important predictors. For non-viral NADCs, though, older age
at ART initiation was far and above the most important predictor. Study aim 2 and study aim 3, thus
have found that in the presence of other study cancer risk factors (i.e. smoking) factors related to
immune response are particularly important in assessing risk for an NADC. While older age is a known
risk factor for cancer, these studies showed just how important an older age at ART initiation was.
Further, from the variation in findings between viral and non-viral associated NADCs, we now
understand just how important it will be to consider NADC sub-sites separately in the future.
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The HIV epidemic has been marked with many advances that increase patient’s survival after
infection, but also discovery of new complications, such as cancer. The findings of this dissertation
emphasize the burden of NADCs in the HIV infected population, especially anal, liver, lung, prostate, and
Hodgkin’s lymphoma. Age and immune response factors were most predictive of NADC risk, but to
varying degrees in viral-related and non-viral related NADCs. As survival improves and this population
continues to age, chronic conditions such as cancer will be at the forefront of patient care management.
We understand the impact screening for cancer can have in the general population. Now, it is
imperative to understand how to shape those guidelines to better address cancer in the HIV-infected
population by screening earlier and more often and looking closely at the interplay between wellestablished and new predictive factors.
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